<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Indian J Med Res</journal-id><journal-id journal-id-type="iso-abbrev">Indian J Med Res</journal-id><journal-id journal-id-type="pmc-domain-id">1431</journal-id><journal-id journal-id-type="pmc-domain">ijmedres</journal-id><journal-id journal-id-type="publisher-id">IJMR</journal-id><journal-id journal-id-type="publisher-id">Indian J Med Res</journal-id><journal-title-group><journal-title>The Indian Journal of Medical Research</journal-title></journal-title-group><issn pub-type="ppub">0971-5916</issn><publisher><publisher-name>Scientific Scholar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9552389</article-id><article-id pub-id-type="pmcid-ver">PMC9552389.1</article-id><article-id pub-id-type="pmcaid">9552389</article-id><article-id pub-id-type="pmcaiid">9552389</article-id><article-id pub-id-type="pmid">35859436</article-id><article-id pub-id-type="doi">10.4103/ijmr.IJMR_474_21</article-id><article-id pub-id-type="publisher-id">IJMR-155-91</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>Safety &amp; effectiveness of COVID-19 vaccines: A narrative review</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Chirico</surname><given-names initials="F">Francesco</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor1" ref-type="corresp"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>da Silva</surname><given-names initials="JAT">Jaime A. Teixeira</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tsigaris</surname><given-names initials="P">Panagiotis</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Sharun</surname><given-names initials="K">Khan</given-names></name><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<italic toggle="yes">Department of Public Health, Post-graduate School of Occupational Medicine, Catholic University of the Sacred Heart, Rome, Italy</italic>
</aff><aff id="aff2">
<label>2</label>
<italic toggle="yes">Independent Researcher, Kagawa-Ken, Japan</italic>
</aff><aff id="aff3">
<label>3</label>
<italic toggle="yes">Department of Economics, Thompson Rivers University, Kamloops, British Columbia, Canada</italic>
</aff><aff id="aff4">
<label>4</label>
<italic toggle="yes">Division of Surgery, ICAR-Indian Veterinary Research Institute, Bareilly, Uttar Pradesh, India</italic>
</aff><author-notes><corresp id="cor1"><italic toggle="yes">For correspondence</italic>: Prof Francesco Chirico, Via Umberto Cagni, 21 20162 Milano, Italy e-mail: <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="medlavchirico@gmail.com">medlavchirico@gmail.com</email></corresp></author-notes><pub-date pub-type="epub-ppub"><month>1</month><year>2022</year></pub-date><pub-date pub-type="ppub"><month>1</month><year>2022</year></pub-date><volume>155</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">418932</issue-id><fpage>91</fpage><lpage>104</lpage><history><date date-type="received"><day>14</day><month>2</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>12</day><month>10</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-09-04 16:25:15.233"><day>04</day><month>09</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>Copyright: &#169; 2022 Indian Journal of Medical Research</copyright-statement><copyright-year>2022</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbyncsalicense">https://creativecommons.org/licenses/by-nc-sa/4.0/</ali:license_ref><license-p>This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="IJMR-155-91.pdf"/><abstract><p>There are currently eight vaccines against SARS-CoV-2 that have received Emergency Use Authorization by the WHO that can offer some protection to the world&#8217;s population during the COVID-19 pandemic. Though research is being published all over the world, public health officials, policymakers and governments are collecting evidence-based information to establish the public health policies. Unfortunately, continued international travel, violations of lockdowns and social distancing, the lack of mask use, the emergence of mutant strains of the virus and lower adherence by a sector of the global population that remains sceptical of the protection offered by vaccines, or about any risks associated with vaccines, hamper these efforts. Here we examine the literature on the efficacy, effectiveness and safety of COVID-19 vaccines, with an emphasis on select categories of individuals and against new SARS-CoV-2 strains. The literature shows that these eight vaccines are highly effective in protecting the population from severe disease and death, but there are some issues concerning safety and adverse effects. Further, booster shots and variant-specific vaccines would also be required.</p></abstract><kwd-group><kwd>Adverse effect</kwd><kwd>clinical trials</kwd><kwd>COVID-19</kwd><kwd>efficacy</kwd><kwd>neutralization potential</kwd><kwd>risks</kwd><kwd>safety</kwd><kwd>SARS-CoV-2</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC-SA</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p>The World Health Organization (WHO) list of Emergency Use Authorization (EUA)-qualified COVID-19 vaccines (as on 20 December, 2021) contains eight vaccines, namely the three adenoviral-vectored vaccines ChAdOx1 nCoV-19 (University of Oxford/AstraZeneca), Ad26.CoV2.S (Janssen), Covishield, CrAdOxI, nCoV-19 (Serum Institute of India), two whole-inactivated coronavirus, which are the Covilo/BBIBP-CorV (SinoPharm/Beijing Institute of Biological Products), CoronaVac (Sinovac) and Covaxin, BBV152 (Bharat Biotech), and the messenger RNA (mRNA) vaccines mRNA-1273 (Moderna) and BNT162b2 (Pfizer-BioNTech)<xref rid="R1" ref-type="bibr">1</xref>. mRNA vaccines work by injecting mRNA that encodes the SARS-CoV-2 spike protein directly into the host and have several advantages over conventional vaccine types, including improved safety, low potential for mutations, lower risk of antigen degradation <italic toggle="yes">in vivo</italic> and the potential for rapid mass production at a lower cost<xref rid="R2" ref-type="bibr">2</xref>, although there are still challenges remaining regarding their pharmacological stability<xref rid="R3" ref-type="bibr">3</xref>.</p><p>Another mRNA vaccine, CureVac, was developed in the European Union (EU) by CureVac N.V. and the Coalition for Epidemic Preparedness Innovations, with the hope of being cheaper and lasting longer than other mRNA vaccines, but results on June 16, 2021 from a 40,000-person phase III two-dose trial found it 47 per cent effective at preventing the disease, which was lower than the &#8805;50 per cent requirement for approval by the WHO<xref rid="R4" ref-type="bibr">4</xref>. Other vaccines produced by Janssen, AstraZeneca, Sputnik-V and CanSino, use human and primate adenovirus vectors<xref rid="R5" ref-type="bibr">5</xref>. The vaccines manufactured by Novavax and GSK/Sanofi companies consist of purified pre-fusion stabilized SARS-CoV-2 spike protein, which is given in combination with an adjuvant to boost the immune response<xref rid="R6" ref-type="bibr">6</xref>. On June 1, 2021, the WHO validated the use of the Chinese Sinovac - CoronaVac COVID-19 vaccine for emergency use, although with interim policy recommendations<xref rid="R7" ref-type="bibr">7</xref>. CoronaVac is an inactivated vaccine with easy storage requirements<xref rid="R8" ref-type="bibr">8</xref>. It was only 51 per cent effective at preventing COVID-19 in late-stage trials<xref rid="R9" ref-type="bibr">9</xref>. The vaccine&#8217;s safety, immunogenicity and efficacy need to be tested across the three phases of clinical trials, although &#8216;protection against severe disease and death is difficult to assess only in phase 3 clinical trials&#8217;<xref rid="R10" ref-type="bibr">10</xref>.</p><p>Vaccination against COVID-19 started in India on January 16, 2021<xref rid="R11" ref-type="bibr">11</xref>. The Indian government and States launched an extensive vaccination campaign against COVID-19, targeting 300 million beneficiaries of priority groups such as healthcare and frontline workers and individuals older than 50<xref rid="R12" ref-type="bibr">12</xref>. India&#8217;s drug regulator (Central Drugs and Standards Committee - CDSCO) approved restricted emergency use of Covishield and Covaxin in India. Covishield (AstraZeneca vaccine ChAdOx1/AZD1222), approved for EUA by the WHO, is a two-dose version of the Oxford/AstraZeneca vaccine manufactured by the Serum Institute of India<xref rid="R13" ref-type="bibr">13</xref>, while Covaxin (BBV152 vaccine) is an inactivated-virus vaccine<xref rid="R11" ref-type="bibr">11</xref><xref rid="R14" ref-type="bibr">14</xref>. Phase I (safety and immunogenicity) and phase II trial (immune response and safety) data of Covaxin are published<xref rid="R15" ref-type="bibr">15</xref>. A phase 3 study confirmed the clinical efficacy of BBV152 against symptomatic COVID-19 disease and safety monitoring and assessment did not raise concerns about the vaccine<xref rid="R16" ref-type="bibr">16</xref>.</p><p>In April 2021, the Indian Government approved Sputnik V as a third vaccine<xref rid="R12" ref-type="bibr">12</xref>. Sputnik V (Gam-COVID-Vac), which is a dual vector-based vaccine that combines type 26 and rAd5 recombinant adenovirus (rAd), exhibited 91.6 per cent efficacy against COVID-19<xref rid="R17" ref-type="bibr">17</xref>. Sinopharm&#8217;s BBIBP-CorV (Covilo) showed 79 per cent efficacy against symptomatic SARS-CoV-2 infection and hospitalization in a large multi-country phase III trial after administering two doses 21 days apart, but efficacy could not be determined in people aged 60+ and with comorbidities, and there was an underrepresentation of women<xref rid="R18" ref-type="bibr">18</xref>.</p><p>In October 2021, India crossed the one billion vaccine doses milestone and by January 16, 2022, 70 per cent adult population was fully vaccinated<xref rid="R19" ref-type="bibr">19</xref>.</p><sec><title>Efficacy/effectiveness of current COVID-19 vaccines</title><p>A systematic review on the efficacy of vaccines covering studies from January 1 to May 14, 2021 identified 30 studies, showed 80-90 per cent vaccine efficacy against symptomatic and asymptomatic infections in fully vaccinated people in nearly all studies<xref rid="R20" ref-type="bibr">20</xref>. In clinical trials, three vaccines had higher (&gt;90%) efficacy against COVID-19 infection [Pfizer-BioNTech (~95%), Moderna (~94%) and Sputnik V (~92%)] than the vaccines by Oxford-AstraZeneca (~70%) and Janssen (54-72%), against moderate and severe forms of COVID-19 infection<xref rid="R10" ref-type="bibr">10</xref>. The mRNA vaccines showed high efficacy against infection and a very high level of protection against severe disease, hospitalization and death while the risk of severe forms of COVID-19 infection and deaths was reduced by Moderna, Sputnik V, Janssen and Oxford-AstraZeneca vaccines. In contrast, this information was not available in the published trials for the Pfizer-BioNTech vaccine<xref rid="R20" ref-type="bibr">20</xref><xref rid="R21" ref-type="bibr">21</xref>. Compared to the Pfizer vaccine, the Moderna vaccine can be kept at higher temperatures, making it easier to transport and store<xref rid="R22" ref-type="bibr">22</xref>. Other vaccines produced by other companies, and with positive efficacy results, received EUA status in some countries<xref rid="R23" ref-type="bibr">23</xref>. The longitudinal assessment of vaccine participants is a necessary critical assessment because it provides information on whether vaccination can achieve long-lasting immunity<xref rid="R24" ref-type="bibr">24</xref>.</p><p>Although most evidence suggests that &#8216;immune responses elicited by SARS-CoV-2 infection are present and might protect against&#8217; reinfection, but the experience with seasonal coronaviruses and the present experience with SARS-CoV-2 suggest that immunity to natural infection might wane over time, as reinfection cases occur<xref rid="R25" ref-type="bibr">25</xref>. For this reason, an extra booster dose can continue to offer protection<xref rid="R26" ref-type="bibr">26</xref>.</p><p>Regarding the interchangeability of COVID-19 vaccines, the WHO recommends using the same COVID-19 vaccine for both doses of a two-dose schedule<xref rid="R27" ref-type="bibr">27</xref>, but there is scientific evidence of the effectiveness of heterologous vaccination with AstraZeneca or Covishield as the first dose and an mRNA vaccine as the second dose<xref rid="R28" ref-type="bibr">28</xref><xref rid="R29" ref-type="bibr">29</xref><xref rid="R30" ref-type="bibr">30</xref>.</p></sec><sec><title>Safety and adverse effects of current COVID-19 vaccines</title><p>As shown in <xref rid="T1" ref-type="table">Table I</xref>, current vaccines have demonstrated considerable efficacy in diminishing mild, moderate and severe cases with a low risk of adverse events<xref rid="R21" ref-type="bibr">21</xref>. For some of these vaccines [such as Convidicea (AD5-nCoV), Janssen (Ad26.COV2.S), Sinopharm (BBIBP-CorV), Covaxin (BBV152) and Sinovac (CoronaVac)], there is the information available on their immunogenicity and safety from phase I and II vaccine recipients, but evidence of their effectiveness is not clear<xref rid="R21" ref-type="bibr">21</xref>. Due to urgency, health regulatory agencies such as the EMA in the EU and the Food and Drug Administration (FDA) in the US evaluated only short-term adverse effects before their authorization. Records of adverse events in trial results on the BNT162b2 mRNA COVID-19 vaccine (Pfizer-BioNTech vaccine) continued up to six months from the second dose<xref rid="R39" ref-type="bibr">39</xref>. Mild-to-moderate local responses such as discomfort, redness or inflammation at the injection site were the most commonly reported adverse effects in the clinical trials, while systemic events included fatigue, headache, body aches and fever<xref rid="R39" ref-type="bibr">39</xref>. There were four serious issues among BNT162b2 participants in a clinical trial: shoulder injury from vaccine administration, right axillary lymphadenopathy, paroxysmal ventricular arrhythmia and right leg paresthesia<xref rid="R39" ref-type="bibr">39</xref>. Another adverse reaction in the Pfizer-BioNTech trial was lymphadenopathy with 64 vaccine recipients (0.3%) versus only six in the placebo group (&lt;0.1%)<xref rid="R39" ref-type="bibr">39</xref>. The clinical trial on the mRNA-1273 COVID-19 vaccine, manufactured by ModernaTX Inc., reported no serious adverse events, while moderate or mild adverse events included headache, fatigue, myalgia, chills and injection-site discomfort, but these were dose-dependent and more common after the second immunization<xref rid="R40" ref-type="bibr">40</xref>.</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table I</label><caption><p>Type, regime, efficacy, safety, protection against variants and storage of COVID-19 vaccines listed by the World Health Organization: Findings from clinical trials and preliminary studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">COVID-19 vaccine</th><th align="left" rowspan="1" colspan="1">Country; date of WHO&#8217;s listing</th><th align="left" rowspan="1" colspan="1">Type of vaccine and regimen</th><th align="left" rowspan="1" colspan="1">Efficacy and safety profile against original virus and variants of concern</th><th align="left" rowspan="1" colspan="1">Storage</th><th align="center" rowspan="1" colspan="1">Cost per dose (US$)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Pfizer BioNTech SE (BNT162b2)<xref rid="R31" ref-type="bibr">31</xref></td><td align="left" rowspan="1" colspan="1">USA, January 31, 2020</td><td align="left" rowspan="1" colspan="1">m-RNA vaccine <break/>2 doses regimen <break/>Three weeks apart <break/>Use for &gt;12 yr old (for 12-15 yr children with comorbidities this vaccine is suggested)</td><td align="left" rowspan="1" colspan="1">92-100% against infection <break/>87% against hospitalization <break/>92% against severe disease <break/>A possible causal relationship with very rare cases of myocarditis in young men (16-24) is reported and currently under investigation<xref rid="R41" ref-type="bibr">41</xref>
<break/>75% reduction in neutralization activity against the Beta (B.1351), 88% reduction against Gamma (P1) and Delta (B1.617.2) variants, and 93% reduction against Alpha (B.1.1.7)</td><td align="left" rowspan="1" colspan="1">&#8722;70&#176;C for shipping and six months storage <break/>2-8&#176;C for 30 days</td><td align="center" rowspan="1" colspan="1">20</td></tr><tr><td align="left" rowspan="1" colspan="1">Spikevax (Moderna, mRNA-1273)<xref rid="R32" ref-type="bibr">32</xref></td><td align="left" rowspan="1" colspan="1">USA; April 30, 2021</td><td align="left" rowspan="1" colspan="1">m-RNA-vaccine <break/>2 doses regimen <break/>Four weeks apart <break/>Use for &gt;18 yr old</td><td align="left" rowspan="1" colspan="1">94% against infection <break/>100% against severe disease, hospitalization and death (<italic toggle="yes">e.g</italic>., anaphylaxis) <break/>A possible causal relationship with very rare cases of myocarditis in young men is reported and currently under investigation <break/>Preliminary results indicate some reduction in neutralization activity against the Beta (B.1351) variant, and less marked decrease against Gamma (P1), Alpha (B.1.1.7), and Epsilon (B.1.429). The impact of delta (B.1617.2) is yet to be determined</td><td align="left" rowspan="1" colspan="1">&#8722;20&#176;C for shipping and six months storage <break/>2-8&#176;C for 30 days</td><td align="center" rowspan="1" colspan="1">37</td></tr><tr><td align="left" rowspan="1" colspan="1">Janssen (Johnson and Johnson) (Ad26.CoV2)<xref rid="R33" ref-type="bibr">33</xref></td><td align="left" rowspan="1" colspan="1">March 12, 2021</td><td align="left" rowspan="1" colspan="1">Viral vector <break/>Single dose regimen <break/>Use for &gt;18 yr old</td><td align="left" rowspan="1" colspan="1">66% against infection <break/>77% (after 14 days) to 86% (after 28 days) against severe disease <break/>93% (after 14 days) to 100% (after 28 days) against hospitalization <break/>Efficacy was maintained against P2 and B1.351 variants <break/>Very rare severe allergic reactions reported in clinical trials <break/>Thrombosis with thrombocytopenia syndrome reported 3-15 days following vaccination</td><td align="left" rowspan="1" colspan="1">2-8&#176;C for three months &#8722;20&#176;C for two years</td><td align="center" rowspan="1" colspan="1">10</td></tr><tr><td align="left" rowspan="1" colspan="1">Vaxzevria (Oxford/Astrazeneca) (ChAdOx1)<xref rid="R34" ref-type="bibr">34</xref></td><td align="left" rowspan="1" colspan="1">UK, February 15, 2021</td><td align="left" rowspan="1" colspan="1">Viral vector <break/>Two doses regimen <break/>Four weeks apart for two standard doses <break/>12 wk apart for &#189; dose and full dose use for &gt;18 yr old</td><td align="left" rowspan="1" colspan="1">92% protection against hospitalization with delta variant; 86% protection against hospitalization with Alfa variant <break/>No severe allergic reactions reported in clinical trials <break/>Thrombosis with thrombocytopenia syndrome reported 3-30 days following vaccination</td><td align="left" rowspan="1" colspan="1">2-8&#176;C (pharmacy) for six months</td><td align="center" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">CoronaVac (Sinovac Biotech Ltd)<xref rid="R35" ref-type="bibr">35</xref></td><td align="left" rowspan="1" colspan="1">China, June 1, 2021</td><td align="left" rowspan="1" colspan="1">Whole cell inactivated vaccine <break/>Two doses regime <break/>Two-four weeks apart <break/>Use for&gt;18 yr old</td><td align="left" rowspan="1" colspan="1">50-84% against infection <break/>80-100% in preventing severe COVID-19 infections, hospitalization and deaths <break/>51-83.5% in preventing symptomatic COVID-19 infection <break/>Safe and well tolerated in older adults <break/>49.6% against infection (P. 1 variant) <break/>50.7% (P. 2 variant)</td><td align="left" rowspan="1" colspan="1">2-8&#176;C pharmacy refrigerator</td><td align="center" rowspan="1" colspan="1">30</td></tr><tr><td align="left" rowspan="1" colspan="1">Covishield&#8482; (Serum Institute of India Pvt. Ltd) (ChAdOx1-S)<xref rid="R36" ref-type="bibr">36</xref></td><td align="left" rowspan="1" colspan="1">India, February 15, 2021</td><td align="left" rowspan="1" colspan="1">Viral vector <break/>Two doses regimen <break/>Four weeks apart for two standard doses <break/>12 wk apart for &#189; dose and full dose use for &gt;18 yr old</td><td align="left" rowspan="1" colspan="1">72-85% against infection <break/>92% protection against hospitalization with delta variant; 86% protection against hospitalization with Alfa variant <break/>No severe allergic reactions reported in clinical trials <break/>Thrombosis with thrombocytopenia syndrome reported 3-30 days following vaccination</td><td align="left" rowspan="1" colspan="1">2-8&#176;C (pharmacy) for six months</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">BIBP/Sinopharma (Beijing BioInstitute of Biological Products Co. Ltd)<xref rid="R37" ref-type="bibr">37</xref></td><td align="left" rowspan="1" colspan="1">China, May 7, 2021</td><td align="left" rowspan="1" colspan="1">Whole cell inactivated vaccine <break/>Two doses regime <break/>Three-four weeks apart <break/>Use for &gt;18 yr old</td><td align="left" rowspan="1" colspan="1">79% against infection and hospitalization <break/>No severe allergic reactions reported in clinical trials</td><td align="left" rowspan="1" colspan="1">2-8&#176;C (pharmacy)</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Covaxin (Bharat Biotech BBV152)<xref rid="R38" ref-type="bibr">38</xref></td><td align="left" rowspan="1" colspan="1">India, November 3, 2021</td><td align="left" rowspan="1" colspan="1">Whole virion inactivated vaccine <break/>Two doses regimen <break/>Four weeks apart <break/>Use for &gt;18 yr</td><td align="left" rowspan="1" colspan="1">78% efficacy against infection, hospitalization and deaths</td><td align="left" rowspan="1" colspan="1">2-8&#176;C (pharmacy)</td><td align="center" rowspan="1" colspan="1">15-20</td></tr></tbody></table><table-wrap-foot><fn><p>Information gathered above from various sources can be also validated from: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mckinsey.com" ext-link-type="uri">https://www.mckinsey.com</ext-link>/industries/pharmaceuticals-and-medical-products/our-insights/on-pins-and-needles-will-COVID-19-vaccines-save-the-world</italic> and <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.statista.com" ext-link-type="uri">https://www.statista.com</ext-link>/chart/23510/estimated-effectiveness-of-COVID-19-vaccine-candidates</italic>/. Cost per dose obtained from: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.statista.com" ext-link-type="uri">https://www.statista.com</ext-link>/chart/23658/reported-cost-per-dose-of-COVID-19-vaccines/</italic> and <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://observer.com" ext-link-type="uri">https://observer.com</ext-link>/2020/08/COVID19-vaccine-</italic>
<italic toggle="yes">price-comparison-moderna-pfizer-novavax-johnson-astrazeneca</italic>/. All vaccines report mild-to-moderate local reactions (<italic toggle="yes">e.g.</italic>, pain, redness, or swelling at the injection) and a few systemic events (<italic toggle="yes">e.g</italic>., fatigue, headache, body aches, and fever), For information on protection against variants see: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.businessinsider.in" ext-link-type="uri">https://www.businessinsider.in</ext-link>/science/news/one-chart-shows-how-well-covid-19-vaccines-work-against-the-3-most-worrisome-coronavirus-variants/articleshow/81472174.cms</italic>, WHO. Background document on the Bharat Biotech BBV152 Covaxin vaccine against COVID-19. Released on November 3, 2021. Available from: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int" ext-link-type="uri">https://extranet.who.int</ext-link>/iris/restricted/bitstream/handle/10665/347044/WHO-2019-nCoV-vaccines-SAGE-recommendation-BBV152-background-2021.1-eng.pdf?sequence=1&amp;isAllowed=y</italic>; For the cost of Covaxin: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.dnaindia.com" ext-link-type="uri">https://www.dnaindia.com</ext-link>/india/report-bharat-biotech-announces-price-of-Covaxin-rs-600-for-states-rs-1200-for-private-hospitals-2887737.</italic></p></fn></table-wrap-foot></table-wrap><p>Myocarditis and pericarditis were reported in individuals receiving mRNA vaccines (Pfizer-BioNTech BNT162b2 and Moderna SpikeVax), especially in young males after the second dose, so the US Centres for Disease Control and Prevention (CDC) and FDA developed educational material for vaccine recipients and providers that described the possibility of myocarditis and its symptoms to be able to recognize and manage it<xref rid="R41" ref-type="bibr">41</xref>. There are insufficient data to describe the efficacy, safety and effectiveness of the BNT162b2 in children under 16 and the SpikeVax vaccine in individuals under 18<xref rid="R42" ref-type="bibr">42</xref>. Although the balance of benefits and risks varied by age and gender, but the benefits of preventing the COVID-19 disease and associated hospitalizations, intensive care unit admissions and deaths outweighed the risks such as expected myocarditis cases after vaccination in all populations for which vaccination was recommended<xref rid="R41" ref-type="bibr">41</xref>. There are currently no alternatives to mRNA COVID-19 vaccines for youths, so on May 10, 2021, the FDA expanded the EUA of the Pfizer-BioNTech COVID-19 vaccine to include adolescents 12 through 15 yr of age<xref rid="R41" ref-type="bibr">41</xref>.</p><p>Anaphylaxis has been the only life-threatening condition reported during the vaccination campaign with the Pfizer-BioNTech vaccine, so it has to be appropriately managed and prevented<xref rid="R43" ref-type="bibr">43</xref>. Hypersensitivity-related adverse events for Pfizer-BioNTech and Moderna trial participants relative to the placebo groups were 0.12 and 0.4 per cent higher, respectively<xref rid="R39" ref-type="bibr">39</xref><xref rid="R40" ref-type="bibr">40</xref>. In addition, the Pfizer-BioNTech trial reported one &#8216;drug hypersensitivity reaction&#8217; and one case of anaphylaxis, while Moderna reported two cases of &#8216;delayed hypersensitivity reactions&#8217;<xref rid="R44" ref-type="bibr">44</xref>.</p><p>By December 23, 2020, among the 1,893,360 first doses of Pfizer-BioNTech vaccines administered in the US, only 0.2 per cent of adverse events were reported and submitted to the Vaccine Adverse Event Reporting System (VAERS)<xref rid="R45" ref-type="bibr">45</xref>. As of January 10, 2021, a reported 4,041,396 first doses of Moderna COVID-19 vaccine had been administered in the United States, and reports of 1,266 (0.03%) adverse events after receipt of Moderna COVID-19 vaccine were submitted to VAERS<xref rid="R46" ref-type="bibr">46</xref>.</p><p>Allergic reactions from the two available mRNA COVID-19 vaccines were due to polyethylene glycol (PEG)<xref rid="R47" ref-type="bibr">47</xref>, also known as macrogol, while for the AstraZeneca and Johnson and Johnson COVID-19 vaccines, the filler polysorbate 80, also known as Tween 80, has been implicated in allergic reactions<xref rid="R48" ref-type="bibr">48</xref><xref rid="R49" ref-type="bibr">49</xref><xref rid="R50" ref-type="bibr">50</xref>. Allergic reactions are rare, but the CDC recommends avoiding mRNA vaccines in individuals who had anaphylaxis in the past<xref rid="R42" ref-type="bibr">42</xref><xref rid="R51" ref-type="bibr">51</xref>. In addition, the CDC guidance indicates precaution for allergy due to &#8216;a potential cross-reactive hypersensitivity between ingredients in mRNA and adenovirus vector COVID-19 vaccines&#8217;<xref rid="R52" ref-type="bibr">52</xref>.</p><p>The occurrence of thrombosis with thrombocytopenia syndrome was linked to adenovirus vector vaccines such as ChAdOx1 nCoV-19 (Oxford-AstraZeneca) and AD26.CoV2&#183;S (Johnson and Johnson), raising concerns<xref rid="R43" ref-type="bibr">43</xref>. For example, a population-based cohort study in Denmark and Norway showed &#8216;increased rates of venous thromboembolic events, including cerebral venous thrombosis&#8217; in recipients of ChAdOx1, more venous thromboembolic events were observed in the vaccinated cohort than expected in the general population, and the standardized morbidity ratio was significantly greater than unity<xref rid="R53" ref-type="bibr">53</xref>.</p><p>ChAdOx1 nCoV-19 vaccine induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis with fatal intracerebral haemorrhaging<xref rid="R53" ref-type="bibr">53</xref><xref rid="R54" ref-type="bibr">54</xref><xref rid="R55" ref-type="bibr">55</xref>. Following administration of the Johnson &amp; Johnson vaccine, a case of thrombocytopenia, elevated D-dimers and pulmonary emboli was found<xref rid="R56" ref-type="bibr">56</xref>. EMA reported other blood clots associated with thrombocytopenia, including arterial thromboses and splanchnic vein thrombosis, after administration of the AstraZeneca vaccine<xref rid="R57" ref-type="bibr">57</xref>. All patients in each series had high levels of antibodies against antigenic complexes of platelet factor 4, as seen in heparin-induced thrombocytopenia. Therefore, this condition was defined as &#8216;vaccine-induced immune thrombotic thrombocytopenia&#8217;, requiring high-dose immunoglobulins and certain non-heparin anticoagulants for treatment<xref rid="R57" ref-type="bibr">57</xref><xref rid="R58" ref-type="bibr">58</xref>. A case report of Guillain&#8722;Barre syndrome followed the administration of the first dose of the ChAdOx1 vaccine<xref rid="R59" ref-type="bibr">59</xref>, and two cases of autoimmune hepatitis were triggered by Covishield vaccination<xref rid="R60" ref-type="bibr">60</xref>.</p><p>The Coalition of Epidemic Preparedness Innovations (CEPI) questioned the use of alum and other adjuvants that might promote T-helper2 (Th2) responses<xref rid="R61" ref-type="bibr">61</xref>. Moreover, T-helper17 (Th17) inflammatory responses, which play a role in the pathogenesis of COVID-19-related pneumonia and oedema by promoting eosinophilic activation and infiltration, could also explain coronavirus-vaccine immune enhancement<xref rid="R62" ref-type="bibr">62</xref>. Therefore, an understanding of Th17 responses is critical for the successful clinical development and production of COVID-19 vaccines and plays a potential role in selecting vaccine dose, adjuvants and route<xref rid="R62" ref-type="bibr">62</xref>.</p><p>Do COVID-19 vaccines sensitize humans to antibody-dependent enhanced (ADE) breakthrough infection? ADE is a complex phenomenon that includes vaccine hypersensitivity (VAH), delayed-type hypersensitivity and/or an Arthus reaction<xref rid="R63" ref-type="bibr">63</xref>. VAH has a complex and poorly defined immunopathology post-vaccination outcome that may be associated with non-protective antibodies<xref rid="R64" ref-type="bibr">64</xref>. ADE in SARS-CoV and MERS-CoV infection showed the development of poorly or non-neutralizing antibodies after vaccination or infection enhance subsequent infections<xref rid="R65" ref-type="bibr">65</xref>. Several SARS-CoV and MERS-CoV vaccines have elicited a post-challenge VAH in laboratory animals. For example, in the 1960s, the formalin-inactivated measles vaccine in children caused VAH 8-12 months after the vaccination, leading to lung lesions, revealing damage to parenchymal tissue, pulmonary neutrophilia with abundant macrophages and lymphocytes and excess eosinophils<xref rid="R66" ref-type="bibr">66</xref>. Lessons learned from adverse effects caused by SARS-CoV and MERS-CoV vaccines may help to develop better immunotherapeutics and vaccines against SARS-CoV-2<xref rid="R65" ref-type="bibr">65</xref>.</p><p>Overvaccination in patients predisposed to autoimmune disease may enhance the possibility of developing an autoimmune response<xref rid="R63" ref-type="bibr">63</xref>. Since the mRNA vaccines against COVID-19 are the first mRNA vaccines authorized for the market, there is a possibility that these may generate strong type 1 interferon responses that could lead to inflammation and autoimmune conditions<xref rid="R67" ref-type="bibr">67</xref>.</p><p>A vaccine in the market requires safety monitoring surveillance to detect and evaluate rare adverse events not identified in prelicensure clinical trials. In the US, the CDC has three long-standing vaccine safety programmes: VAERS, the Vaccine Safety Datalink and the Clinical Immunization Safety Assessment<xref rid="R68" ref-type="bibr">68</xref>.</p></sec><sec><title>Efficacy of the vaccines against new viral strains</title><p>Considering that the SARS-CoV-2 virus, like other viruses, mutates<xref rid="R69" ref-type="bibr">69</xref><xref rid="R70" ref-type="bibr">70</xref>, why are some RNA vaccines effective against the new strains of the SARS-CoV-2 virus, while others are less, or not at all? These new variants result from mutations in the viral genomes, occurring due to the consequences of viral replication, which are advantageous to the survival of the virus. Among these variants, WHO, US CDC, and the EU&#8217;s European Centre for Disease Prevention identified some variants as being significant variants, referring to them as variants of concern (VOCs) and variants of interest (VOIs) (<xref rid="T2" ref-type="table">Table II</xref>). VOCs emerged as a more significant threat to public health due to their enhanced transmissibility and infectivity<xref rid="R71" ref-type="bibr">71</xref>. Global concern is the continued spread of the highly transmissible Delta variant, which has become predominant worldwide<xref rid="R72" ref-type="bibr">72</xref><xref rid="R73" ref-type="bibr">73</xref> and has better transmission potential (60%) than the alpha variant<xref rid="R74" ref-type="bibr">74</xref>. Currently, omicron variant is becoming the predominant strain resulting from a combination of increased transmissibility and the ability to evade natural and artificial immunization<xref rid="R75" ref-type="bibr">75</xref>. WHO monitors the global spread and epidemiology of VOCs and VOIs and coordinates laboratory investigations<xref rid="R76" ref-type="bibr">76</xref>.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table II</label><caption><p>Characteristics of SARS-CoV-2 variants of concern (VOC, Alpha, Beta, Gamma, Delta and omicron) and variants of interest (VOI, Lambda and Mu)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Variant</th><th align="center" rowspan="1" colspan="1">Next strain</th><th align="center" rowspan="1" colspan="1">Lineages</th><th align="center" rowspan="1" colspan="1">First detected</th><th align="center" rowspan="1" colspan="1">Country</th><th align="center" rowspan="1" colspan="1">Date designated</th><th align="center" rowspan="1" colspan="1">Spread number of nations</th><th align="left" rowspan="1" colspan="1">Attributes</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Variants of concern</td><td align="left" rowspan="1" colspan="1">Alpha</td><td align="center" rowspan="1" colspan="1">20I/501Y.V1</td><td align="center" rowspan="1" colspan="1">B.1.1.7</td><td align="center" rowspan="1" colspan="1">September 2020</td><td align="center" rowspan="1" colspan="1">UK</td><td align="center" rowspan="1" colspan="1">December 18, 2020</td><td align="center" rowspan="1" colspan="1">173</td><td align="left" rowspan="1" colspan="1">Evidence of increased transmissibility (~50% increase) and disease severity based on case fatality and hospitalizations rates</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Beta</td><td align="center" rowspan="1" colspan="1">20H/501.V2</td><td align="center" rowspan="1" colspan="1">B.1.351 <break/>B.1.351.2 <break/>B.1.351.3</td><td align="center" rowspan="1" colspan="1">May 2020</td><td align="center" rowspan="1" colspan="1">South Africa</td><td align="center" rowspan="1" colspan="1">December 18, 2020</td><td align="center" rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">Evidence of increased transmissibility (~50% increase) and has an impact on therapeutics (bamlanivimab and etesevimab) and vaccines (reduced neutralization by post-vaccination serum)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Gamma</td><td align="center" rowspan="1" colspan="1">20J/501Y.V3</td><td align="center" rowspan="1" colspan="1">P. 1 <break/>P. 1.1 <break/>P. 1.2</td><td align="center" rowspan="1" colspan="1">November 2020</td><td align="center" rowspan="1" colspan="1">Brazil</td><td align="center" rowspan="1" colspan="1">January 11, 2021</td><td align="center" rowspan="1" colspan="1">74</td><td align="left" rowspan="1" colspan="1">Evidence of impact on monoclonal antibody treatments (bamlanivimab and etesevimab) and vaccines (reduced neutralization by post-vaccination serum)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Delta</td><td align="center" rowspan="1" colspan="1">21A/S: 478K</td><td align="center" rowspan="1" colspan="1">B.1.617.2 <break/>AY.1 <break/>AY.2 <break/>AY.3</td><td align="center" rowspan="1" colspan="1">October 2020</td><td align="center" rowspan="1" colspan="1">India</td><td align="center" rowspan="1" colspan="1">May 11, 2021 (VOI: 4 April 2021)</td><td align="center" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Evidence of increased transmissibility and has an impact on monoclonal antibody treatments and vaccines (reduced neutralization by post-vaccination serum)</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Omicron</td><td align="center" rowspan="1" colspan="1">21K</td><td align="center" rowspan="1" colspan="1">B.1.1.529</td><td align="center" rowspan="1" colspan="1">November 2021</td><td align="center" rowspan="1" colspan="1">Multiple countries</td><td align="center" rowspan="1" colspan="1">November 26, 2021</td><td align="center" rowspan="1" colspan="1">Not reported yet</td><td align="left" rowspan="1" colspan="1">Not fully investigated yet</td></tr><tr><td align="left" rowspan="1" colspan="1">Variants of interest</td><td align="left" rowspan="1" colspan="1">Lambda</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="center" rowspan="1" colspan="1">C.37</td><td align="center" rowspan="1" colspan="1">December 2020</td><td align="center" rowspan="1" colspan="1">Peru</td><td align="center" rowspan="1" colspan="1">June 14, 2021</td><td align="center" rowspan="1" colspan="1">N/A</td><td align="left" rowspan="1" colspan="1">N/A</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Mu</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">B.1.621</td><td align="center" rowspan="1" colspan="1">January 2021</td><td align="center" rowspan="1" colspan="1">Columbia</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn><p>Last updated: 20 December 2021. Information obtained from WHO (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int" ext-link-type="uri">https://www.who.int</ext-link>/en/activities/tracking-SARS-CoV-2-variants/</italic>) there are a number of variants that are being monitored currently and can be found at the WHO as we as at the USA Center of Disease Control and Prevention found (<italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov" ext-link-type="uri">https://www.cdc.gov</ext-link>/coronavirus/2019-ncov/variants/variant-info.html</italic>); CDC has no VOI listed and only two VOCs: Delta and Omicron; There is also information in the magazine about: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.businessinsider.com" ext-link-type="uri">https://www.businessinsider.com</ext-link>/COVID-19-vaccine-efficacy-variants-india-south-africa-brazil-uk-2021-5</italic>; for transmission see: <italic toggle="yes"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.aljazeera.com" ext-link-type="uri">https://www.aljazeera.com</ext-link>/news/2021/7/7/map-tracking-the-COVID-19-delta-variant</italic>. WHO, World Health Organization; CDC, Centres for Disease Control; VOI, variants of interest; VOCs, variants of concerns; N/A, not available</p></fn></table-wrap-foot></table-wrap><p>Several SARS-CoV-2 VOCs have emerged and were originally identified in the UK (variant B.1.1.7 or alpha), South Africa (B.1.351 or beta), Brazil (P.1 or gamma), India (B.1.617.2 or delta) and South Africa (B.1.1.529 or omicron)<xref rid="R77" ref-type="bibr">77</xref>. These VOCs are considered severe public health threats because of their association with higher transmissibility, morbidity, mortality and potential immune escape<xref rid="R78" ref-type="bibr">78</xref> by infection or vaccine-induced antibodies resulting from the accumulation of mutations in the spike protein<xref rid="R79" ref-type="bibr">79</xref>. In other words, these may alter the clinical manifestation of the disease and efficacy of available vaccines and therapeutics, as well as the ability of reverse transcription-polymerase chain reaction (RT-PCR) assays to detect the virus<xref rid="R80" ref-type="bibr">80</xref>.</p><p>Though the efficacy of the ChAdOx1 nCoV-19 vaccine against the alpha variant was similar to that reported in previous studies<xref rid="R81" ref-type="bibr">81</xref>, the vaccine conferred only minimal protection against COVID-19 infection caused by the Beta variant<xref rid="R82" ref-type="bibr">82</xref>. The NVX-CoV2373 vaccine (Novavax) also demonstrated efficacy against the Alpha and Beta variants of SARS-CoV-2<xref rid="R83" ref-type="bibr">83</xref>. The Novavax vaccine is 86 per cent efficacious against the Alpha variant and 60 per cent efficacious against the Beta variant<xref rid="R84" ref-type="bibr">84</xref>. Although the neutralization capacity of several COVID-19 vaccines (mRNA-1273, NVX-CoV2373, BNT162b2 and ChAdOx1 nCoV-19) was reduced against the Beta (B.1.351) variant<xref rid="R85" ref-type="bibr">85</xref>, but Covaxin conferred significant protection against both Beta (B.1.351) and Delta (B.1.617.2) variants<xref rid="R70" ref-type="bibr">70</xref>.</p><p>Similarly, the single-dose Janssen COVID-19 vaccine candidate demonstrated efficacy against the Beta variant<xref rid="R86" ref-type="bibr">86</xref>. The Moderna vaccine candidate (mRNA-1273) also demonstrated efficacy against the Alpha and Beta SARS-CoV-2 variants, findings that were based on <italic toggle="yes">in vitro</italic> neutralization studies conducted using serum collected from individuals vaccinated with the mRNA-1273 vaccine<xref rid="R87" ref-type="bibr">87</xref>. Therefore, South Africa adjourned campaigns to vaccinate its front-line health care workers (HCWs) with the Oxford-AstraZeneca vaccine after a small clinical trial suggested that it ineffectively prevented mild to moderate illness from the dominant variant in the country<xref rid="R88" ref-type="bibr">88</xref>. The results of a clinical trial confirmed that a two-dose regimen of the ChAdOx1 nCoV-19 (AstraZeneca) vaccine did not protect individuals against the mild-to-moderate B.1.351 variant<xref rid="R89" ref-type="bibr">89</xref>.</p><p>Mutations observed in the SARS-CoV-2 variants identified in the UK and South Africa had small effects on the effectiveness of the Pfizer-BioNTech vaccine<xref rid="R90" ref-type="bibr">90</xref>. A two-strain mathematical framework using Ontario (Canada) as a case study found that, given the levels of under-reporting and case levels at that time, &#8216;a variant strain was unlikely to dominate&#8217; until the first quarter of 2021, and high vaccine efficacy was required across strains to make it possible to have an immune population in Ontario by the end of 2021<xref rid="R91" ref-type="bibr">91</xref>. The UK research showed that the Pfizer&#8211;BioNTech vaccine was 92 per cent effective against symptomatic cases of the alpha variant and offered 83 per cent protection against the Delta variant<xref rid="R92" ref-type="bibr">92</xref>. A study in Qatar found similar results: the Pfizer&#8211;BioNTech vaccine offered 90 per cent protection against the Alpha variant and 75 per cent protection against the Beta variant<xref rid="R93" ref-type="bibr">93</xref>. In a US-based study carried out during July 2021, 346 of the 469 COVID-19 cases (74%) among Massachusetts residents occurred in fully vaccinated people with two doses of Pfizer-BioNTech, Moderna, or a single dose of Janssen vaccine &#8805;14 days before exposure<xref rid="R94" ref-type="bibr">94</xref>. Genomic sequencing of testing identified the new Delta variant in 90 per cent of cases<xref rid="R86" ref-type="bibr">86</xref>. Even vaccinated people may get infected with COVID-19 due to the Delta variant, and on July 27, 2021, the US CDC released a recommendation to invite citizens to wear masks in indoor public environments where the risk of COVID-19 transmission is high<xref rid="R84" ref-type="bibr">84</xref>.</p><p>The neutralization potential of BBV152/Covaxin, the inactivated SARS-CoV-2 vaccine rolled out in India, was also effective against Beta and Delta variants, but since reduced neutralization activity may result in reduced vaccine effectiveness, further studies are needed for Covaxin against these two variants<xref rid="R78" ref-type="bibr">78</xref>. A single dose of Pfizer or AstraZeneca offered little protection against the Beta and Delta variants and a neutralizing response was generated against the Delta variant only after the administration of the second dose<xref rid="R74" ref-type="bibr">74</xref>. Despite being lower, the remaining neutralization capacity conferred by the Pfizer vaccine against Delta and other VOCs was protective<xref rid="R95" ref-type="bibr">95</xref>.</p><p>Until February 6, 2022, the WHO described eight variants of interest (VOIs), namely Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37)and Mu (B.1.621)<xref rid="R96" ref-type="bibr">96</xref>. However, there is still a lack of detailed knowledge about their transmissibility, infectivity, re-infectivity, immune escape and vaccine activity<xref rid="R61" ref-type="bibr">61</xref>. A preprint highlighted that the lambda variant (lineage C.37), which spread from Peru in December 2020, displayed increased infectivity and immune escape against the Coronovac vaccine<xref rid="R97" ref-type="bibr">97</xref>. <xref rid="T2" ref-type="table">Table II</xref> summarizes the profiles of the VOCs and VOIs. The most recent data on the variants reported in India are available at the Indian SARS-CoV-2 Genomic Consortia (INSACOG) website. The predominant SARS-CoV-2 variant currently circulating in India is Delta (B.1.617.2 and AY.4)<xref rid="R98" ref-type="bibr">98</xref>. Covaxin (BBV152) exhibited good protection (65.2%) against the Delta variant, and although a minor reduction in the neutralizing antibody titre was observed, the sera of vaccinated individuals still effectively neutralized the Delta, Delta AY.1 and B.1.617.3 variants<xref rid="R99" ref-type="bibr">99</xref>. In contrast, breakthrough infections were reported due to the Delta variant in individuals fully vaccinated with Covishield<xref rid="R100" ref-type="bibr">100</xref>.</p></sec><sec><title>Safety and efficacy of the vaccines in select categories of people</title><p>Another issue is that clinical trials are studies conducted on select categories of individuals, generally healthy people. Thus, concerns exist about safety and effectiveness in specific categories of people. For instance, there are doubts that all COVID-19 vaccines can stimulate an immune response in older individuals (&#8805;65 yr), especially those with co-morbidities, such as hypertension, obesity and diabetes mellitus<xref rid="R101" ref-type="bibr">101</xref>. Older patients, especially those older than 65 and with co-morbidities, are more susceptible to a severe form of COVID-19 that can progress rapidly, often leading to death<xref rid="R102" ref-type="bibr">102</xref>. In general, the efficacy of vaccines in older people is not well studied. The impact of immunosenescence on vaccine safety is even more uncertain<xref rid="R2" ref-type="bibr">2</xref>. The presence of chronic diseases (<italic toggle="yes">e.g</italic>., diabetes) and fragility, including immunodepression, may be better forecasters of weak immunologic responses than age<xref rid="R103" ref-type="bibr">103</xref>.</p><p>Even though the safety and efficacy of COVID-19 vaccines in older people are critical to their health<xref rid="R2" ref-type="bibr">2</xref>, no studies have been done to examine the response of this category of individuals to all COVID-19 vaccines. Vaccines developed by the University of Oxford/AstraZeneca (ChAdOx1) and Janssen (Ad26.COV2) depend on the genetic alteration of adenoviruses that are inactivated, due to the replacement of the <italic toggle="yes">E1</italic> gene with the spike gene<xref rid="R2" ref-type="bibr">2</xref>. The ChAdOx1 nCoV-19 (AZD1222) vaccine is better tolerated by older than younger people, and after the second dose, it has similar immunogenicity across all ages<xref rid="R104" ref-type="bibr">104</xref>. However, additional assessment of AZD1222 is planned<xref rid="R105" ref-type="bibr">105</xref>. A second trial on the Moderna vaccine showed binding- and neutralizing-antibody responses in older people (&gt;55 yr), similar to previously reported vaccine recipients between 18 and 55 yr of age<xref rid="R40" ref-type="bibr">40</xref>.</p><p>Pregnant and lactating women are excluded from vaccine research because they are not recognized as a high-priority group, despite the risk of complications and poor perinatal outcomes<xref rid="R106" ref-type="bibr">106</xref>, and because of previous experience of pregnancies complicated by infection with other coronaviruses, such as SARS-CoV and MERS-CoV, making pregnant women vulnerable to severe SARS-CoV-2 disease<xref rid="R107" ref-type="bibr">107</xref>. A retrospective study based on the clinical criteria confirmed that pregnancy significantly increased the risk of severe COVID-19<xref rid="R108" ref-type="bibr">108</xref>. Based on a review of maternal and neonatal COVID-19 morbidity and mortality data, the COVID-19 vaccines should be administered to those at the highest risk of severe infection until the safety and efficacy of vaccines are thoroughly validated<xref rid="R109" ref-type="bibr">109</xref>. Therefore, in consultation with their obstetricians, pregnant women will need to consider the benefits and risks of COVID-19 vaccines. The US CDC, the American College of Obstetricians and Gynaecologists and the Society for Maternal-Foetal Medicine each issued guidance supporting vaccination in pregnant individuals<xref rid="R110" ref-type="bibr">110</xref>.</p><p>Another critical issue concerns COVID-19 vaccination in children. Children of any age are susceptible to SARS-CoV-2 infection, including severe disease manifestations. Previously healthy children are also at risk of severe COVID-19 and multisystem inflammatory syndrome in children (MIS-C)<xref rid="R68" ref-type="bibr">68</xref>. Children might differ from adults in terms of the safety, reactogenicity and immunogenicity of vaccines<xref rid="R68" ref-type="bibr">68</xref>. Paediatric clinical trials can offer direct and indirect benefits from COVID-19 vaccination<xref rid="R111" ref-type="bibr">111</xref>.</p></sec><sec><title>Updates on COVID-19 and vaccines</title><p>On November 26, 2021, the WHO designated B.1.1.529 (Omicron) as a new VoC, although its pathogenicity as well as its potential to evade immune response from vaccines and natural immunity is relatively unknown<xref rid="R112" ref-type="bibr">112</xref>. Since other variants could emerge in the future, coordinated global responses that address vaccines and lockdown measures against SARS-CoV-2, surveillance systems that monitor viral mutations and the effectiveness of vaccines, as well as overcoming vaccine and economic inequalities, are needed.</p><p>A third dose of the Pfizer-BioNTech vaccine is effective in protecting individuals against severe COVID-19-related outcomes, compared with receiving only two doses at least five months prior<xref rid="R113" ref-type="bibr">113</xref>. A booster of Moderna or Pfizer-BioNTech may produce antibodies against SARS-CoV-2 in organ transplant patients with an immunodepression state<xref rid="R114" ref-type="bibr">114</xref><xref rid="R115" ref-type="bibr">115</xref>. On August 13, 2021, the US FDA authorized a third dose of the Pfizer-BioNTech or Moderna vaccines for immunocompromised people, who are particularly at risk for severe disease<xref rid="R116" ref-type="bibr">116</xref>, and the EMA concluded that an extra dose of these COVID-19 vaccines may be given to these patients at least 28 days after their second dose<xref rid="R117" ref-type="bibr">117</xref>.</p></sec></body><back><fn-group><fn fn-type="supported-by"><p><bold><italic toggle="yes">Financial support &amp; sponsorship</italic>:</bold> None.</p></fn><fn fn-type="COI-statement"><p><bold><italic toggle="yes">Conflicts of Interest</italic>:</bold> None.</p></fn></fn-group><ref-list><title>References</title><ref id="R1"><label>1</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Status of COVID-19 vaccines within WHO EUL/PQ evaluation process</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf">https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_19August2021.pdf</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Soiza</surname><given-names>RL</given-names></name><name name-style="western"><surname>Scicluna</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomson</surname><given-names>EC</given-names></name></person-group><article-title>Efficacy and safety of COVID-19 vaccines in older people</article-title><source>Age Ageing</source><year>2021</year><volume>50</volume><fpage>279</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">33320183</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/ageing/afaa274</pub-id><pub-id pub-id-type="pmcid">PMC7799251</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Crommelin</surname><given-names>DJA</given-names></name><name name-style="western"><surname>Anchordoquy</surname><given-names>TJ</given-names></name><name name-style="western"><surname>Volkin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Jiskoot</surname><given-names>W</given-names></name><name name-style="western"><surname>Mastrobattista</surname><given-names>E</given-names></name></person-group><article-title>Addressing the cold reality of mRNA vaccine stability</article-title><source>J Pharm Sci</source><year>2021</year><volume>110</volume><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">33321139</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.xphs.2020.12.006</pub-id><pub-id pub-id-type="pmcid">PMC7834447</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Dolgin</surname><given-names>E</given-names></name></person-group><article-title>CureVac COVID vaccine let-down spotlights mRNA design challenges</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>483</fpage><pub-id pub-id-type="pmid">34145413</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-01661-0</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>SAC</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2:An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="webpage" publication-format="web"><source>GlaxoSmithKline. Sanofi and GSK COVID-19 vaccine candidate demonstrates strong immune responses across all adult age groups in Phase 2 trial</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong-immune-responses-across-all-adult-age-groups-in-phase-2-trial/">https://www.gsk.com/en-gb/media/press-releases/sanofi-and-gsk-covid-19-vaccine-candidate-demonstrates-strong -immune-responses- across-all-adult-age-groups-in-phase-2-trial/</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. WHO validates Sinovac COVID-19 vaccine for emergency use and issue interim policy recommendations</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-2021.1">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines -SAGE_recommendation-Sinovac-CoronaVac-2021.1</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>ZW</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older:A randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><fpage>803</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">33548194</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30987-7</pub-id><pub-id pub-id-type="pmcid">PMC7906628</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mallapaty</surname><given-names>S</given-names></name></person-group><article-title>WHO approval of Chinese CoronaVac COVID vaccine will be crucial to curbing pandemic</article-title><source>Nature</source><year>2021</year><volume>594</volume><fpage>161</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">34089030</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-01497-8</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hodgson</surname><given-names>SH</given-names></name><name name-style="western"><surname>Mansatta</surname><given-names>K</given-names></name><name name-style="western"><surname>Mallett</surname><given-names>G</given-names></name><name name-style="western"><surname>Harris</surname><given-names>V</given-names></name><name name-style="western"><surname>Emary</surname><given-names>KRW</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name></person-group><article-title>What defines an efficacious COVID-19 vaccine?A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2</article-title><source>Lancet Infect Dis</source><year>2021</year><volume>21</volume><fpage>e26</fpage><lpage>35</lpage><pub-id pub-id-type="pmid">33125914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30773-8</pub-id><pub-id pub-id-type="pmcid">PMC7837315</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>VM</given-names></name><name name-style="western"><surname>Pandi-Perumal</surname><given-names>SR</given-names></name><name name-style="western"><surname>Trakht</surname><given-names>I</given-names></name><name name-style="western"><surname>Thyagarajan</surname><given-names>SP</given-names></name></person-group><article-title>Strategy for COVID-19 vaccination in India:The country with the second highest population and number of cases</article-title><source>NPJ Vaccines</source><year>2021</year><volume>6</volume><fpage>60</fpage><pub-id pub-id-type="pmid">33883557</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41541-021-00327-2</pub-id><pub-id pub-id-type="pmcid">PMC8169891</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="webpage" publication-format="web"><source>Ministry of Health and Family Welfare, Government of India. COVID-19 vaccine operational guidelines</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://main.mohfw.gov.in/sites/default/files/COVID19VaccineOG111Chapter16.pdf">https://main.mohfw.gov.in/sites/default/files/COVID19VaccineOG111Chapter16.pdf</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sasikala</surname><given-names>M</given-names></name><name name-style="western"><surname>Shashidhar</surname><given-names>J</given-names></name><name name-style="western"><surname>Deepika</surname><given-names>G</given-names></name><name name-style="western"><surname>Ravikanth</surname><given-names>V</given-names></name><name name-style="western"><surname>Krishna</surname><given-names>VV</given-names></name><name name-style="western"><surname>Sadhana</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Immunological memory and neutralizing activity to a single dose of COVID-19 vaccine in previously infected individuals</article-title><source>Int J Infect Dis</source><year>2021</year><volume>108</volume><fpage>183</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">34022331</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2021.05.034</pub-id><pub-id pub-id-type="pmcid">PMC8132551</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>J</given-names></name><name name-style="western"><surname>Saurabh</surname><given-names>S</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Verma</surname><given-names>MK</given-names></name><name name-style="western"><surname>Goel</surname><given-names>AD</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>MK</given-names></name><etal/></person-group><article-title>COVID-19 vaccine hesitancy among medical students in India</article-title><source>Epidemiol Infect</source><year>2021</year><volume>149</volume><fpage>e132</fpage><pub-id pub-id-type="pmid">34011421</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268821001205</pub-id><pub-id pub-id-type="pmcid">PMC8185413</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Thiagarajan</surname><given-names>K</given-names></name></person-group><article-title>What do we know about India's Covaxin vaccine?</article-title><source>BMJ</source><year>2021</year><volume>373</volume><fpage>n997</fpage><pub-id pub-id-type="pmid">33879478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n997</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name><name name-style="western"><surname>Blackwelder</surname><given-names>W</given-names></name><name name-style="western"><surname>Potdar</surname><given-names>V</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>P</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name><etal/></person-group><article-title>Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152):interim results of a randomised, double-bind, controlled, phase 3 trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2173</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">34774196</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02000-6</pub-id><pub-id pub-id-type="pmcid">PMC8584828</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>AI</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>AS</given-names></name><etal/></person-group><article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine:An interim analysis of a randomised controlled phase 3 trial in Russia</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>671</fpage><lpage>81</lpage><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. The sinopharm COVID-19 vaccine: what you need to know</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/news-room/feature-stories/detail/the-sinopharm-covid-19-vaccine-what-you-need-to-know">https://www.who.int/news-room/feature-stories/detail/the -sinopharm-covid-19-vaccine-what-you-need-to-know</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. India marks one year of COVID vaccination</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.who.int/India/news/feature-stories/detail/India-marks-one-year-of-covid-vaccination">http://www.who.int/India/news/feature-stories/detail/India- marks-one-year-of-covid-vaccination</uri></comment><date-in-citation>accessed on January 7, 2022</date-in-citation></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Harder</surname><given-names>T</given-names></name><name name-style="western"><surname>Koch</surname><given-names>J</given-names></name><name name-style="western"><surname>Vygen-Bonnet</surname><given-names>S</given-names></name><name name-style="western"><surname>K&#252;lper-Schiek</surname><given-names>W</given-names></name><name name-style="western"><surname>Pilic</surname><given-names>A</given-names></name><name name-style="western"><surname>Reda</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection:Interim results of a living systematic review, 1 January to 14 May 2021</article-title><source>Euro Surveill</source><year>2021</year><volume>26</volume><fpage>2100563</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2021.26.28.2100563</pub-id><pub-id pub-id-type="pmcid">PMC8284046</pub-id><pub-id pub-id-type="pmid">34269175</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Doroftei</surname><given-names>B</given-names></name><name name-style="western"><surname>Ciobica</surname><given-names>A</given-names></name><name name-style="western"><surname>Ilie</surname><given-names>OD</given-names></name><name name-style="western"><surname>Maftei</surname><given-names>R</given-names></name><name name-style="western"><surname>Ilea</surname><given-names>C</given-names></name></person-group><article-title>Discussing the reliability and efficiency of COVID-19 vaccines</article-title><source>Diagnostics</source><year>2021</year><volume>11</volume><fpage>579</fpage><pub-id pub-id-type="pmid">33804914</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/diagnostics11040579</pub-id><pub-id pub-id-type="pmcid">PMC8063839</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Meo</surname><given-names>SA</given-names></name><name name-style="western"><surname>Bukhari</surname><given-names>IA</given-names></name><name name-style="western"><surname>Akram</surname><given-names>J</given-names></name><name name-style="western"><surname>Meo</surname><given-names>AS</given-names></name><name name-style="western"><surname>Klonoff</surname><given-names>DC</given-names></name></person-group><article-title>COVID-19 vaccines:Comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna vaccines</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2021</year><volume>25</volume><fpage>1663</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">33629336</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.26355/eurrev_202102_24877</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sadarangani</surname><given-names>M</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>A</given-names></name><name name-style="western"><surname>Kollmann</surname><given-names>TR</given-names></name></person-group><article-title>Immunological mechanisms of vaccine-induced protection against COVID-19 in humans</article-title><source>Nat Rev Immunol</source><year>2021</year><volume>21</volume><fpage>475</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">34211186</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-021-00578-z</pub-id><pub-id pub-id-type="pmcid">PMC8246128</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Forni</surname><given-names>G</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>COVID-19 vaccines:Where we stand and challenges ahead</article-title><source>Cell Death Differ</source><year>2021</year><volume>28</volume><fpage>626</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">33479399</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41418-020-00720-9</pub-id><pub-id pub-id-type="pmcid">PMC7818063</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Cohen</surname><given-names>JI</given-names></name><name name-style="western"><surname>Burbelo</surname><given-names>PD</given-names></name></person-group><article-title>Reinfection with SARS-CoV-2:Implications for vaccines</article-title><source>Clin Infect Dis</source><year>2020</year><volume>73</volume><fpage>e4223</fpage><lpage>28</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa1866</pub-id><pub-id pub-id-type="pmcid">PMC7799323</pub-id><pub-id pub-id-type="pmid">33338197</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>JH</given-names></name><name name-style="western"><surname>Marks</surname><given-names>F</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>JD</given-names></name></person-group><article-title>Looking beyond COVID-19 vaccine phase 3 trials</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>205</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">33469205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01230-y</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim statement on booster doses for COVID-19 vaccination</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination---update-22-december-2021">www.who.int/news/item/22-12-2021-interim-statement- on-booster-doses-for-covid-19-vaccination---update-22-december-2021</uri></comment><date-in-citation>accessed on January 7, 2022</date-in-citation></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>RH</given-names></name><name name-style="western"><surname>Stuart</surname><given-names>ASV</given-names></name><name name-style="western"><surname>Greenland</surname><given-names>M</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>NJ</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV):A single-blind, randomised, non-inferiority trial</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>856</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">34370971</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01694-9</pub-id><pub-id pub-id-type="pmcid">PMC8346248</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Normark</surname><given-names>J</given-names></name><name name-style="western"><surname>Vikstr&#246;m</surname><given-names>L</given-names></name><name name-style="western"><surname>Gwon</surname><given-names>YD</given-names></name><name name-style="western"><surname>Persson</surname><given-names>IL</given-names></name><name name-style="western"><surname>Edin</surname><given-names>A</given-names></name><name name-style="western"><surname>Bj&#246;rsell</surname><given-names>T</given-names></name><etal/></person-group><article-title>Heterologous ChAdOx1 nCoV-19 and mRNA1273 vaccination</article-title><source>New Engl J Med</source><year>2021</year><volume>385</volume><fpage>1049</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">34260850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2110716</pub-id><pub-id pub-id-type="pmcid">PMC8314734</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vall&#233;e</surname><given-names>A</given-names></name><name name-style="western"><surname>Vasse</surname><given-names>M</given-names></name><name name-style="western"><surname>Mazaux</surname><given-names>L</given-names></name><name name-style="western"><surname>Bonan</surname><given-names>B</given-names></name><name name-style="western"><surname>Amiel</surname><given-names>C</given-names></name><name name-style="western"><surname>Zia-Chahabi</surname><given-names>S</given-names></name><etal/></person-group><article-title>An immunogenicity report for the comparison between heterologous and homologous prime-boost schedules with ChAdOx1-S and BNT162b2 vaccines</article-title><source>J Clin Med</source><year>2021</year><volume>10</volume><fpage>3817</fpage><pub-id pub-id-type="pmid">34501264</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/jcm10173817</pub-id><pub-id pub-id-type="pmcid">PMC8432244</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim recommendations for use of the Pfizer-BioNTech COVID-19 vaccine, BNT162b2, under emergency use listing: guidance, 8 January 2021</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://apps.who.int/iris/handle/10665/338484">http://apps.who.int/iris/handle/10665/338484</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19: interim guidance, 25 January 2021</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://apps.who.int/iris/handle/10665/338862">http://apps.who.int/iris/handle/10665/338862</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim recommendations for use of the Janssen Ad26.COV2.5 (COVID-19) vaccine: interim guidance, first issued 17 march 2021, updated 15 June 2021</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://apps.who.int/iris/handle/10655/341784">http://apps.who.int/iris/handle/10655/341784</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 vaccine AZD1222 Vaxzevria&#8482;, SII COVISHIELDTM)</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1">www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-AZD1222-2021.1</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. The Sinovac-CoronaVac COVID-19 vaccine: What you need to know, 2 September 2021</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know">http://www.who.int/news-room/feature-stories/detail/the-sinovac-covid-19-vaccine-what-you-need-to-know</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. WHO recommendation Serum Institute of India Pvt Ltd- COVID-19 Vaccine (ChAdOxl-S [recombinant])-COVISHIELDTM</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-covishield">http://extranet.who.int/pqweb/vaccines/covid-19-vaccine-chadox1-s-recombinant-covishield</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG) Sinopharm</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP">https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-BIBP</uri></comment><date-in-citation>accessed on September 22, 2021</date-in-citation></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Interim recommendations for use of the Bharat Biotech BBV152 COVAXIN<sup>R</sup> vaccine against COVID-19</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin">www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-bbv152-covaxin</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2603</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>NG</given-names></name><name name-style="western"><surname>Widge</surname><given-names>AT</given-names></name><name name-style="western"><surname>Jackson</surname><given-names>LA</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>PC</given-names></name><name name-style="western"><surname>Makhene</surname><given-names>M</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults</article-title><source>N Engl J Med</source><year>2020</year><volume>383</volume><fpage>2427</fpage><lpage>38</lpage><pub-id pub-id-type="pmid">32991794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2028436</pub-id><pub-id pub-id-type="pmcid">PMC7556339</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gargano</surname><given-names>JW</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>M</given-names></name><name name-style="western"><surname>Hadler</surname><given-names>SC</given-names></name><name name-style="western"><surname>Langley</surname><given-names>G</given-names></name><name name-style="western"><surname>Su</surname><given-names>JR</given-names></name><name name-style="western"><surname>Oster</surname><given-names>ME</given-names></name><etal/></person-group><article-title>Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients:Update from the Advisory Committee on Immunization Practices &#8211;United States, June 2021</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2021</year><volume>70</volume><fpage>977</fpage><lpage>82</lpage><pub-id pub-id-type="pmid">34237049</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7027e2</pub-id><pub-id pub-id-type="pmcid">PMC8312754</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Banerji</surname><given-names>A</given-names></name><name name-style="western"><surname>Wickner</surname><given-names>PG</given-names></name><name name-style="western"><surname>Saff</surname><given-names>R</given-names></name><name name-style="western"><surname>Stone</surname><given-names>CA</given-names><suffix>Jr</suffix></name><name name-style="western"><surname>Robinson</surname><given-names>LB</given-names></name><name name-style="western"><surname>Long</surname><given-names>AA</given-names></name><etal/></person-group><article-title>mRNA vaccines to prevent COVID-19 disease and reported allergic reactions:Current evidence and suggested approach</article-title><source>J Allergy Clin Immunol Pract</source><year>2021</year><volume>9</volume><fpage>1423</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">33388478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaip.2020.12.047</pub-id><pub-id pub-id-type="pmcid">PMC7948517</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Long</surname><given-names>B</given-names></name><name name-style="western"><surname>Bridwell</surname><given-names>R</given-names></name><name name-style="western"><surname>Gottlieb</surname><given-names>M</given-names></name></person-group><article-title>Thrombosis with thrombocytopenia syndrome associated with COVID-19 vaccines</article-title><source>Am J Emerg Med</source><year>2021</year><volume>49</volume><fpage>58</fpage><lpage>61</lpage><pub-id pub-id-type="pmid">34062319</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2021.05.054</pub-id><pub-id pub-id-type="pmcid">PMC8143907</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="webpage" publication-format="web"><source>U.S. Food and Drug Administration. Pfizer-BioNTech COVID-19 Vaccine (BNT162, PF-07302048) [FDA Briefing Document]</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/media/144246/download">https://www.fda.gov/media/144246/download</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shimabukuro</surname><given-names>T</given-names></name><name name-style="western"><surname>Nair</surname><given-names>N</given-names></name></person-group><article-title>Allergic Reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine</article-title><source>JAMA</source><year>2021</year><volume>325</volume><fpage>780</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">33475702</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.2021.0600</pub-id><pub-id pub-id-type="pmcid">PMC8892260</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Shimabukuro</surname><given-names>T</given-names></name></person-group><article-title>Allergic reactions including anaphylaxis after receipt of the first dose of moderna COVID-19 vaccine &#8211;United States, December 21, 2020-January 10 2021</article-title><source>Am J Transplant</source><year>2021</year><volume>21</volume><fpage>1326</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">33641268</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/ajt.16517</pub-id><pub-id pub-id-type="pmcid">PMC8013433</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kounis</surname><given-names>NG</given-names></name><name name-style="western"><surname>Koniari</surname><given-names>I</given-names></name><name name-style="western"><surname>de Gregorio</surname><given-names>C</given-names></name><name name-style="western"><surname>Velissaris</surname><given-names>D</given-names></name><name name-style="western"><surname>Petalas</surname><given-names>K</given-names></name><name name-style="western"><surname>Brinia</surname><given-names>A</given-names></name><etal/></person-group><article-title>Allergic reactions to current available COVID-19 vaccinations:Pathophysiology, causality, and therapeutic considerations</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>221</fpage><pub-id pub-id-type="pmid">33807579</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9030221</pub-id><pub-id pub-id-type="pmcid">PMC7999280</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Erdeljic</surname><given-names>Turk V</given-names></name></person-group><article-title>Anaphylaxis associated with the mRNA COVID-19 vaccines:Approach to allergy investigation</article-title><source>Clin Immunol</source><year>2021</year><volume>227</volume><fpage>10</fpage><fpage>8748</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clim.2021.108748</pub-id><pub-id pub-id-type="pmcid">PMC8080508</pub-id><pub-id pub-id-type="pmid">33932618</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Garvey</surname><given-names>LH</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>S</given-names></name></person-group><article-title>Anaphylaxis to the first COVID-19 vaccine:Is polyethylene glycol (PEG) the culprit?</article-title><source>Br J Anaesth</source><year>2021</year><volume>126</volume><fpage>e106</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">33386124</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.bja.2020.12.020</pub-id><pub-id pub-id-type="pmcid">PMC7834677</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sellaturay</surname><given-names>P</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>S</given-names></name><name name-style="western"><surname>Islam</surname><given-names>S</given-names></name><name name-style="western"><surname>Gurugama</surname><given-names>P</given-names></name><name name-style="western"><surname>Ewan</surname><given-names>PW</given-names></name></person-group><article-title>Polyethylene glycol (PEG) is a cause of anaphylaxis to the Pfizer/BioNTech mRNA COVID-19 vaccine</article-title><source>Clin Exp Allergy</source><year>2021</year><volume>51</volume><fpage>861</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">33825239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/cea.13874</pub-id><pub-id pub-id-type="pmcid">PMC8251011</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Caminati</surname><given-names>M</given-names></name><name name-style="western"><surname>Guarnieri</surname><given-names>G</given-names></name><name name-style="western"><surname>Senna</surname><given-names>G</given-names></name></person-group><article-title>Who is really at risk for anaphylaxis due to COVID-19 vaccine?</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>38</fpage><pub-id pub-id-type="pmid">33440794</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9010038</pub-id><pub-id pub-id-type="pmcid">PMC7827676</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="webpage" publication-format="web"><source>American College of Allergy, Asthma, &amp; Immunology. ACAAI updates to guidance on risk of allergic reactions to COVID-19 vaccines</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://acaai.org/news/acaai-updates-guidance-risk-allergic-reactions-covid-19-vaccines">https://acaai.org/news/acaai-updates-guidance -risk-allergic-reactions-covid-19-vaccines</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Potteg&#229;rd</surname><given-names>A</given-names></name><name name-style="western"><surname>Lund</surname><given-names>LC</given-names></name><name name-style="western"><surname>Karlstad</surname><given-names>&#216;</given-names></name><name name-style="western"><surname>Dahl</surname><given-names>J</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>M</given-names></name><name name-style="western"><surname>Hallas</surname><given-names>J</given-names></name><etal/></person-group><article-title>Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway:Population based cohort study</article-title><source>BMJ</source><year>2021</year><volume>373</volume><fpage>n1114</fpage><pub-id pub-id-type="pmid">33952445</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n1114</pub-id><pub-id pub-id-type="pmcid">PMC8097496</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Suresh</surname><given-names>P</given-names></name><name name-style="western"><surname>Petchey</surname><given-names>W</given-names></name></person-group><article-title>ChAdOx1 nCOV-19 vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis (CVST)</article-title><source>BMJ Case Rep</source><year>2021</year><volume>14</volume><fpage>e243931</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2021-243931</pub-id><pub-id pub-id-type="pmcid">PMC8211078</pub-id><pub-id pub-id-type="pmid">34135077</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bano</surname><given-names>F</given-names></name><name name-style="western"><surname>Badugama</surname><given-names>B</given-names></name><name name-style="western"><surname>Chandra</surname><given-names>D</given-names></name></person-group><article-title>Thrombosis and thrombocytopaenia after ChAdOx1 nCoV-19 vaccination:A single UK centre experience</article-title><source>BMJ Case Rep</source><year>2021</year><volume>14</volume><fpage>e243894</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2021-243894</pub-id><pub-id pub-id-type="pmcid">PMC8278891</pub-id><pub-id pub-id-type="pmid">34257129</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Malik</surname><given-names>B</given-names></name><name name-style="western"><surname>Kalantary</surname><given-names>A</given-names></name><name name-style="western"><surname>Rikabi</surname><given-names>K</given-names></name><name name-style="western"><surname>Kunadi</surname><given-names>A</given-names></name></person-group><article-title>Pulmonary embolism, transient ischaemic attack and thrombocytopenia after the Johnson &amp;Johnson COVID-19 vaccine</article-title><source>BMJ Case Rep</source><year>2021</year><volume>14</volume><fpage>e243975</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2021-243975</pub-id><pub-id pub-id-type="pmcid">PMC8280905</pub-id><pub-id pub-id-type="pmid">34261635</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="webpage" publication-format="web"><source>European Medicines Agency. AstraZeneca's COVID-19 Vaccine: EMA Finds Possible Link to Very Rare Cases of Unusual Blood Clots with Low Blood Platelets</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood">https://www.ema.europa.eu/en/news/astrazenecas-covid-19-vaccine-ema-finds-possible-link-very-rare-cases-unusual-blood-clots-low-blood</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hunter</surname><given-names>PR</given-names></name></person-group><article-title>Thrombosis after COVID-19 vaccination</article-title><source>BMJ</source><year>2021</year><volume>373</volume><fpage>n958</fpage><pub-id pub-id-type="pmid">33853865</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n958</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>SU</given-names></name><name name-style="western"><surname>Khurram</surname><given-names>R</given-names></name><name name-style="western"><surname>Lakhani</surname><given-names>A</given-names></name><name name-style="western"><surname>Quirk</surname><given-names>B</given-names></name></person-group><article-title>Guillain-Barre syndrome following the first dose of the chimpanzee adenovirus-vectored COVID-19 vaccine, ChAdOx1</article-title><source>BMJ Case Rep</source><year>2021</year><volume>14</volume><fpage>e242956</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bcr-2021-242956</pub-id><pub-id pub-id-type="pmcid">PMC8070856</pub-id><pub-id pub-id-type="pmid">33888484</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rela</surname><given-names>M</given-names></name><name name-style="western"><surname>Jothimani</surname><given-names>D</given-names></name><name name-style="western"><surname>Vij</surname><given-names>M</given-names></name><name name-style="western"><surname>Rajakumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Rammohan</surname><given-names>A</given-names></name></person-group><article-title>Auto-immune hepatitis following COVID vaccination</article-title><source>J Autoimmun</source><year>2021</year><volume>123</volume><fpage>102688</fpage><pub-id pub-id-type="pmid">34225251</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jaut.2021.102688</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="webpage" publication-format="web"><source>CEPI. Consensus considerations on the assessment of the risk of disease enhancement with COVID-19 vaccines: Outcome of a coalition for epidemic preparedness from the CEPI alliance</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://taskforce.org/brighton-collaboration-cepi-covid-19-web-conference/">https://taskforce.org/brighton-collaboration-cepi-covid-19-web-conference/</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hotez</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Bottazzi</surname><given-names>ME</given-names></name><name name-style="western"><surname>Corry</surname><given-names>DB</given-names></name></person-group><article-title>The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement</article-title><source>Microbes Infect</source><year>2020</year><volume>22</volume><fpage>165</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">32305501</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.micinf.2020.04.005</pub-id><pub-id pub-id-type="pmcid">PMC7162764</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Gershwin</surname><given-names>LJ</given-names></name></person-group><article-title>Adverse reactions to vaccination:From anaphylaxis to autoimmunity</article-title><source>Vet Clin North Am Small Anim Pract</source><year>2018</year><volume>48</volume><fpage>279</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">29195924</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cvsm.2017.10.005</pub-id><pub-id pub-id-type="pmcid">PMC7114576</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Halstead</surname><given-names>SB</given-names></name><name name-style="western"><surname>Katzelnick</surname><given-names>L</given-names></name></person-group><article-title>COVID-19 vaccines:Should we fear ADE?</article-title><source>J Infect Dis</source><year>2020</year><volume>222</volume><fpage>1946</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">32785649</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jiaa518</pub-id><pub-id pub-id-type="pmcid">PMC7454712</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Karthik</surname><given-names>K</given-names></name><name name-style="western"><surname>Senthilkumar</surname><given-names>TMA</given-names></name><name name-style="western"><surname>Udhayavel</surname><given-names>S</given-names></name><name name-style="western"><surname>Raj</surname><given-names>GD</given-names></name></person-group><article-title>Role of antibody-dependent enhancement (ADE) in the virulence of SARS-CoV-2 and its mitigation strategies for the development of vaccines and immunotherapies to counter COVID-19</article-title><source>Hum Vaccin Immunother</source><year>2020</year><volume>16</volume><fpage>3055</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">32845733</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2020.1796425</pub-id><pub-id pub-id-type="pmcid">PMC7484565</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Fulginiti</surname><given-names>VA</given-names></name><name name-style="western"><surname>Eller</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Downie</surname><given-names>AW</given-names></name><name name-style="western"><surname>Kempe</surname><given-names>CH</given-names></name></person-group><article-title>Altered reactivity to measles virus. Atypical measles in children previously immunized with inactivated measles virus vaccines</article-title><source>JAMA</source><year>1967</year><volume>202</volume><fpage>1075</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">6072745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1001/jama.202.12.1075</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Porter</surname><given-names>FW</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D</given-names></name></person-group><article-title>mRNA vaccines &#8211;A new era in vaccinology</article-title><source>Nat Rev Drug Discov</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kamidani</surname><given-names>S</given-names></name><name name-style="western"><surname>Rostad</surname><given-names>CA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name></person-group><article-title>COVID-19 vaccine development:A pediatric perspective</article-title><source>Curr Opin Pediatr</source><year>2021</year><volume>33</volume><fpage>144</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">33278108</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/MOP.0000000000000978</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rice</surname><given-names>AM</given-names></name><name name-style="western"><surname>Morales</surname><given-names>AC</given-names></name><name name-style="western"><surname>Ho</surname><given-names>AT</given-names></name><name name-style="western"><surname>Mordstein</surname><given-names>C</given-names></name><name name-style="western"><surname>M&#252;hlhausen</surname><given-names>S</given-names></name><name name-style="western"><surname>Watson</surname><given-names>S</given-names></name><etal/></person-group><article-title>Evidence for strong mutation bias towards, and selection against, U content in SARS-CoV-2:Implications for vaccine design</article-title><source>Mol Biol Evol</source><year>2021</year><volume>38</volume><fpage>67</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">32687176</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/molbev/msaa188</pub-id><pub-id pub-id-type="pmcid">PMC7454790</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="webpage" publication-format="web"><source>COVID-19 Genomics UK Consortium. COG-UK report on SARS-CoV-2 spike mutations of interest in the UK</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cogconsortium.uk/wp-content/uploads/2021/01/Report-2_COG-UK_SARS-CoV-2-Mutations.pdf">https://www.cogconsortium.uk/wp-content/uploads/ 2021/01/Report-2_COG-UK_SARS-CoV-2-Mutations.pdf</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Chakraborty</surname><given-names>C</given-names></name><name name-style="western"><surname>Bhattacharya</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>AR</given-names></name></person-group><article-title>Present variants of concern and variants of interest of severe acute respiratory syndrome coronavirus 2:Their significant mutations in S-glycoprotein, infectivity, re-infectivity, immune escape and vaccines activity</article-title><source>Rev Med Virol</source><year>2021</year><volume>32</volume><fpage>e2270</fpage></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="webpage" publication-format="web"><source>GISAID. Genomic epidemiology of novel coronavirus- Global subsampling</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://nextstrain.org/ncov/gisaid/global">https://nextstrain.org/ncov/gisaid/global</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hadfield</surname><given-names>J</given-names></name><name name-style="western"><surname>Megill</surname><given-names>C</given-names></name><name name-style="western"><surname>Bell</surname><given-names>SM</given-names></name><name name-style="western"><surname>Huddleston</surname><given-names>J</given-names></name><name name-style="western"><surname>Potter</surname><given-names>B</given-names></name><name name-style="western"><surname>Callender</surname><given-names>C</given-names></name><etal/></person-group><article-title>Nextstrain:Real-time tracking of pathogen evolution</article-title><source>Bioinformatics</source><year>2018</year><volume>34</volume><fpage>4121</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">29790939</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/bioinformatics/bty407</pub-id><pub-id pub-id-type="pmcid">PMC6247931</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Planas</surname><given-names>D</given-names></name><name name-style="western"><surname>Veyer</surname><given-names>D</given-names></name><name name-style="western"><surname>Baidaliuk</surname><given-names>A</given-names></name><name name-style="western"><surname>Staropoli</surname><given-names>I</given-names></name><name name-style="western"><surname>Guivel-Benhassine</surname><given-names>F</given-names></name><name name-style="western"><surname>Rajah</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization</article-title><source>Nature</source><year>2021</year><volume>596</volume><fpage>276</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">34237773</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03777-9</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="webpage" publication-format="web"><source>Centers for Disease Control and Prevention. Potential rapid increase of Omicron variant infections in the United States</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical-modeling-outbreak.html">https://cdc.gov/coronavirus/2019-ncov/science/forecasting/mathematical -modeling-outbreak.html</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="webpage" publication-format="web"><source>World Health Organization. Tracking SARS-CoV-2 variants</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/">https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="webpage" publication-format="web"><source>Centers for Disease Control and Prevention. New variants of the virus that causes COVID-19</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html">https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant.html</uri></comment><comment>accessed on December 20, 2021</comment></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>GN</given-names></name><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></name><name name-style="western"><surname>Nyayanit</surname><given-names>DA</given-names></name><name name-style="western"><surname>Patil</surname><given-names>DY</given-names></name><etal/></person-group><article-title>Neutralization of beta and delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin</article-title><source>J Travel Med</source><year>2021</year><volume>28</volume><fpage>taab104</fpage><pub-id pub-id-type="pmid">34230972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jtm/taab104</pub-id><pub-id pub-id-type="pmcid">PMC8344909</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lazarevic</surname><given-names>I</given-names></name><name name-style="western"><surname>Pravica</surname><given-names>V</given-names></name><name name-style="western"><surname>Miljanovic</surname><given-names>D</given-names></name><name name-style="western"><surname>Cupic</surname><given-names>M</given-names></name></person-group><article-title>Immune evasion of SARS-CoV-2 emerging variants:What have we learnt so far?</article-title><source>Viruses</source><year>2021</year><volume>13</volume><fpage>1192</fpage><pub-id pub-id-type="pmid">34206453</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/v13071192</pub-id><pub-id pub-id-type="pmcid">PMC8310325</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sharun</surname><given-names>K</given-names></name><name name-style="western"><surname>Tiwari</surname><given-names>R</given-names></name><name name-style="western"><surname>Dhama</surname><given-names>K</given-names></name><name name-style="western"><surname>Emran</surname><given-names>TB</given-names></name><name name-style="western"><surname>Rabaan</surname><given-names>AA</given-names></name><name name-style="western"><surname>Al Mutair</surname><given-names>A</given-names></name></person-group><article-title>Emerging SARS-CoV-2 variants:Impact on vaccine efficacy and neutralizing antibodies</article-title><source>Hum Vaccin Immunother</source><year>2021</year><volume>17</volume><fpage>3491</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">34161189</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1080/21645515.2021.1923350</pub-id><pub-id pub-id-type="pmcid">PMC8240541</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Emary</surname><given-names>KRW</given-names></name><name name-style="western"><surname>Golubchik</surname><given-names>T</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><name name-style="western"><surname>Ariani</surname><given-names>CV</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B</given-names></name><name name-style="western"><surname>Bibi</surname><given-names>S</given-names></name><etal/></person-group><article-title>Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7):An exploratory analysis of a randomised controlled trial</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>1351</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">33798499</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00628-0</pub-id><pub-id pub-id-type="pmcid">PMC8009612</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="webpage" publication-format="web"><source>University of Oxford. ChAdOx1 nCov-19 provides minimal protection against mild-moderate COVID-19 infection from B.1.351 coronavirus variant in young south African adults</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection-against-mild-moderate-covid-19-infection">https://www.ox.ac.uk/news/2021-02-07-chadox1-ncov-19-provides-minimal-protection- against-mild-moderate-covid-19-infection</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="webpage" publication-format="web"><source>Novavax. Novavax COVID-19 vaccine demonstrates 89.3% efficacy in UK Phase 3 trial</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://ir.novavax.com/2021-01-28-Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial">https://ir.novavax.com/2021-01-28-Novavax-COVID-19-Vaccine-Demonstrates-89-3-Efficacy-in-UK-Phase-3-Trial</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Mahase</surname><given-names>E</given-names></name></person-group><article-title>COVID-19:Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n296</fpage><pub-id pub-id-type="pmid">33526412</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n296</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Abdool Karim</surname><given-names>SS</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>T</given-names></name></person-group><article-title>New SARS-CoV-2 variants &#8211;Clinical, public health, and vaccine implications</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>1866</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">33761203</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2100362</pub-id><pub-id pub-id-type="pmcid">PMC8008749</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="webpage" publication-format="web"><source>Johnson &amp; Johnson. Johnson &amp; Johnson Announces Single-Shot Janssen COVID-19 Vaccine Candidate Met Primary Endpoints in Interim Analysis of Its Phase 3 ENSEMBLE Trial</source><year>2021</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.janssen.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints">https://www.janssen.com/johnson-johnson-announces-single-shot-janssen-covid-19-vaccine-candidate-met-primary-endpoints</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="webpage" publication-format="web"><source>Moderna. Moderna COVID-19 vaccine retains neutralizing activity against emerging variants first identified in the U.K. and the republic of South Africa</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://investors.modernatx.com/news/news-details/2021/Moderna-COVID-19-Vaccine-Retains-Neutralizing-Activity-Against-Emerging-Variants-First-Identified-in-the-U-K--and-the-Republic-of-South-Africa-01-25-2021/default.aspx">https://investors.modernatx.com/news/news-details/2021/Moderna-COVID-19-Vaccine-Retains-Neutralizing-Activity-Against-Emerging- Variants-First-Identified-in-the-U-K--and-the-Republic-of-South-Africa-01-25-2021/default.aspx</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wibmer</surname><given-names>CK</given-names></name><name name-style="western"><surname>Ayres</surname><given-names>F</given-names></name><name name-style="western"><surname>Hermanus</surname><given-names>T</given-names></name><name name-style="western"><surname>Madzivhandila</surname><given-names>M</given-names></name><name name-style="western"><surname>Kgagudi</surname><given-names>P</given-names></name><name name-style="western"><surname>Oosthuysen</surname><given-names>B</given-names></name><etal/></person-group><article-title>SARS-CoV-2 501Y. V2 escapes neutralization by South African COVID-19 donor plasma</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>622</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">33654292</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01285-x</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>CL</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Koen</surname><given-names>AL</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L</given-names></name><etal/></person-group><article-title>Efficacy of the ChAdOx1 nCoV-19 COVID-19 vaccine against the B.1.351 variant</article-title><source>N Engl J Med</source><year>2021</year><volume>384</volume><fpage>1885</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">33725432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102214</pub-id><pub-id pub-id-type="pmcid">PMC7993410</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Zou</surname><given-names>J</given-names></name><name name-style="western"><surname>Fontes-Garfias</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, and N501Y variants by BNT162b2 vaccine-elicited sera</article-title><source>Nat Med</source><year>2021</year><volume>27</volume><fpage>620</fpage><lpage>1</lpage><pub-id pub-id-type="pmid">33558724</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-021-01270-4</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Betti</surname><given-names>M</given-names></name><name name-style="western"><surname>Bragazzi</surname><given-names>N</given-names></name><name name-style="western"><surname>Heffernan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kong</surname><given-names>J</given-names></name><name name-style="western"><surname>Raad</surname><given-names>A</given-names></name></person-group><article-title>Could a new COVID-19 mutant strain undermine vaccination efforts?A mathematical modelling approach for estimating the spread of B.1.1.7 using Ontario, Canada, as a case study</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><fpage>592</fpage><pub-id pub-id-type="pmid">34204918</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines9060592</pub-id><pub-id pub-id-type="pmcid">PMC8227606</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sheikh</surname><given-names>A</given-names></name><name name-style="western"><surname>McMenamin</surname><given-names>J</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>B</given-names></name><name name-style="western"><surname>Robertson</surname><given-names>C</given-names></name></person-group><collab>Public Health Scotland and the EAVE II Collaborators</collab><article-title>SARS-CoV-2 Delta VOC in Scotland:Demographics, risk of hospital admission, and vaccine effectiveness</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>2461</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">34139198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)01358-1</pub-id><pub-id pub-id-type="pmcid">PMC8201647</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Abu-Raddad</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Chemaitelly</surname><given-names>H</given-names></name><name name-style="western"><surname>Butt</surname><given-names>AA</given-names></name></person-group><collab>National Study Group for COVID-19 Vaccination</collab><article-title>Effectiveness of the BNT162b2 COVID-19 vaccine against the B.1.1.7 and B.1.351 variants</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>187</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">33951357</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2104974</pub-id><pub-id pub-id-type="pmcid">PMC8117967</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Brown</surname><given-names>CM</given-names></name><name name-style="western"><surname>Vostok</surname><given-names>J</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>H</given-names></name><name name-style="western"><surname>Burns</surname><given-names>M</given-names></name><name name-style="western"><surname>Gharpure</surname><given-names>R</given-names></name><name name-style="western"><surname>Sami</surname><given-names>S</given-names></name><etal/></person-group><article-title>Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings-Barnstable County, Massachusetts, July 2021</article-title><source>MMWR Morb Mortal Wkly Rep</source><year>2021</year><volume>70</volume><fpage>1059</fpage><lpage>62</lpage><pub-id pub-id-type="pmid">34351882</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15585/mmwr.mm7031e2</pub-id><pub-id pub-id-type="pmcid">PMC8367314</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Lustig</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zuckerman</surname><given-names>N</given-names></name><name name-style="western"><surname>Nemet</surname><given-names>I</given-names></name><name name-style="western"><surname>Atari</surname><given-names>N</given-names></name><name name-style="western"><surname>Kliker</surname><given-names>L</given-names></name><name name-style="western"><surname>Regev-Yochay</surname><given-names>G</given-names></name><etal/></person-group><article-title>Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel</article-title><source>Euro Surveill</source><year>2021</year><volume>26</volume><fpage>2100557</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.2807/1560-7917.ES.2021.26.26.2100557</pub-id><pub-id pub-id-type="pmcid">PMC8326656</pub-id><pub-id pub-id-type="pmid">34212838</pub-id></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="book" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Aleem</surname><given-names>A</given-names></name><name name-style="western"><surname>Akbar Samad</surname><given-names>AB</given-names></name><name name-style="western"><surname>Slenker</surname><given-names>AK</given-names></name></person-group><article-title>Emerging variants of SARS-CoV-2 and novel therapeutics against coronavirus (COVID-19)</article-title><year>2022</year><month>02</month><day>6</day><publisher-loc>In: StatPearls [Internet]. Treasure Island (FL)</publisher-loc><publisher-name>StatPearls publishing</publisher-name><year>2022</year><month>01</month></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Vargas-Herrera</surname><given-names>N</given-names></name><name name-style="western"><surname>Araujo-Castillo</surname><given-names>RV</given-names></name><name name-style="western"><surname>Mestanza</surname><given-names>O</given-names></name><name name-style="western"><surname>Galarza</surname><given-names>M</given-names></name><name name-style="western"><surname>Rojas-Serrano</surname><given-names>N</given-names></name><name name-style="western"><surname>Solari-Zerpa</surname><given-names>L</given-names></name></person-group><article-title>SARS-CoV-2 Lambda and Gamma variants competition in Peru, a country with high seroprevalence</article-title><source>Lancet Reg Health Am</source><year>2022</year><volume>6</volume><fpage>100112</fpage><pub-id pub-id-type="pmid">34812432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lana.2021.100112</pub-id><pub-id pub-id-type="pmcid">PMC8600335</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="webpage" publication-format="web"><source>Ministry of Family and Health Welfare. Department of Biotechnology, Government of India. Council of Scientific and Industrial Research. Indian Council of Medical Research. Indian SARS-CoV-2 genomics surveillance (INSACOG)</source><year>2021</year><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clingen.igib.res.in/covid19genomes/">https://clingen.igib.res.in/covid19genomes/</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Yadav</surname><given-names>PD</given-names></name><name name-style="western"><surname>Sahay</surname><given-names>RR</given-names></name><name name-style="western"><surname>Sapkal</surname><given-names>G</given-names></name><name name-style="western"><surname>Nyayanit</surname><given-names>D</given-names></name><name name-style="western"><surname>Shete</surname><given-names>AM</given-names></name><name name-style="western"><surname>Deshpande</surname><given-names>G</given-names></name><etal/></person-group><article-title>Comparable neutralization of SARS-CoV-2 Delta AY.1 and Delta with individuals sera vaccinated with BBV152</article-title><source>J Travel Med</source><year>2021</year><volume>28</volume><fpage>taab154</fpage><pub-id pub-id-type="pmid">34581415</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/jtm/taab154</pub-id><pub-id pub-id-type="pmcid">PMC8500129</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ujjainiya</surname><given-names>R</given-names></name><name name-style="western"><surname>Tyagi</surname><given-names>A</given-names></name><name name-style="western"><surname>Sardana</surname><given-names>V</given-names></name><name name-style="western"><surname>Naushin</surname><given-names>S</given-names></name><name name-style="western"><surname>Bhatheja</surname><given-names>N</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>K</given-names></name><etal/></person-group><article-title>High failure rate of ChAdOx1 in healthcare workers during Delta variant surge:A case for continued use of masks post-vaccination</article-title><source>medRxiv</source><year>2021</year><comment>doi:10.1101/2021.02.28.21252621</comment></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="webpage" publication-format="web"><source>Nature. The COVID vaccine challenges that lie ahead</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://media.nature.com/original/magazine-assets/d41586-020-03334-w/d41586-020-03334-w.pdf">https://media.nature.com/original/magazine-assets/d41586-020-03334-w/d41586-020-03334-w.pdf</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Sanyaolu</surname><given-names>A</given-names></name><name name-style="western"><surname>Okorie</surname><given-names>C</given-names></name><name name-style="western"><surname>Marinkovic</surname><given-names>A</given-names></name><name name-style="western"><surname>Patidar</surname><given-names>R</given-names></name><name name-style="western"><surname>Younis</surname><given-names>K</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P</given-names></name><etal/></person-group><article-title>Comorbidity and its impact on patients with COVID-19</article-title><source>SN Compr Clin Med</source><year>2020</year><volume>2</volume><fpage>1069</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">32838147</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s42399-020-00363-4</pub-id><pub-id pub-id-type="pmcid">PMC7314621</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Andrew</surname><given-names>MK</given-names></name><name name-style="western"><surname>Shinde</surname><given-names>V</given-names></name><name name-style="western"><surname>Ye</surname><given-names>L</given-names></name><name name-style="western"><surname>Hatchette</surname><given-names>T</given-names></name><name name-style="western"><surname>Haguinet</surname><given-names>F</given-names></name><name name-style="western"><surname>Dos Santos</surname><given-names>G</given-names></name><etal/></person-group><article-title>The importance of frailty in the assessment of influenza vaccine effectiveness against influenza-related hospitalization in elderly people</article-title><source>J Infect Dis</source><year>2017</year><volume>216</volume><fpage>405</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">28931244</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/infdis/jix282</pub-id><pub-id pub-id-type="pmcid">PMC5853583</pub-id></element-citation></ref><ref id="R104"><label>104</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names>MN</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Owens</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002):A single-blind, randomised, controlled, phase 2/3 trial</article-title><source>Lancet</source><year>2021</year><volume>396</volume><fpage>1979</fpage><lpage>93</lpage><pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></element-citation></ref><ref id="R105"><label>105</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M</given-names></name><name name-style="western"><surname>Costa Clemens</surname><given-names>SA</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>SA</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>LY</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Aley</surname><given-names>PK</given-names></name><etal/></person-group><article-title>Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine:A pooled analysis of four randomised trials</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>881</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">33617777</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00432-3</pub-id><pub-id pub-id-type="pmcid">PMC7894131</pub-id></element-citation></ref><ref id="R106"><label>106</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Bardaj&#237;</surname><given-names>A</given-names></name><name name-style="western"><surname>Sevene</surname><given-names>E</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>C</given-names></name><name name-style="western"><surname>Men&#233;ndez</surname><given-names>C</given-names></name><name name-style="western"><surname>Omer</surname><given-names>SB</given-names></name><name name-style="western"><surname>Aguado</surname><given-names>T</given-names></name><etal/></person-group><article-title>The need for a global COVID-19 maternal immunisation research plan</article-title><source>Lancet</source><year>2021</year><volume>397</volume><fpage>e17</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">33508228</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)00146-X</pub-id><pub-id pub-id-type="pmcid">PMC8055754</pub-id></element-citation></ref><ref id="R107"><label>107</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Wastnedge</surname><given-names>EA</given-names></name><name name-style="western"><surname>Reynolds</surname><given-names>RM</given-names></name><name name-style="western"><surname>van Boeckel</surname><given-names>SR</given-names></name><name name-style="western"><surname>Stock</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Denison</surname><given-names>FC</given-names></name><name name-style="western"><surname>Maybin</surname><given-names>JA</given-names></name><etal/></person-group><article-title>Pregnancy and COVID-19</article-title><source>Physiol Rev</source><year>2021</year><volume>101</volume><fpage>303</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">32969772</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1152/physrev.00024.2020</pub-id><pub-id pub-id-type="pmcid">PMC7686875</pub-id></element-citation></ref><ref id="R108"><label>108</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Oakes</surname><given-names>MC</given-names></name><name name-style="western"><surname>Kernberg</surname><given-names>AS</given-names></name><name name-style="western"><surname>Carter</surname><given-names>EB</given-names></name><name name-style="western"><surname>Foeller</surname><given-names>ME</given-names></name><name name-style="western"><surname>Palanisamy</surname><given-names>A</given-names></name><name name-style="western"><surname>Raghuraman</surname><given-names>N</given-names></name><etal/></person-group><article-title>Pregnancy as a risk factor for severe coronavirus 2019 (COVID-19) disease using standardized clinical criteria</article-title><source>Am J Obstet Gynecol</source><year>2021</year><volume>3</volume><fpage>100319</fpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajogmf.2021.100319</pub-id><pub-id pub-id-type="pmcid">PMC7826101</pub-id><pub-id pub-id-type="pmid">33493707</pub-id></element-citation></ref><ref id="R109"><label>109</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Stafford</surname><given-names>IA</given-names></name><name name-style="western"><surname>Parchem</surname><given-names>JG</given-names></name><name name-style="western"><surname>Sibai</surname><given-names>BM</given-names></name></person-group><article-title>The COVID-19 vaccine in pregnancy:Risks, benefits and recommendations</article-title><source>Am J Obstet Gynecol</source><year>2021</year><volume>224</volume><fpage>P484</fpage><lpage>95</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajog.2021.01.022</pub-id><pub-id pub-id-type="pmcid">PMC7847190</pub-id><pub-id pub-id-type="pmid">33529575</pub-id></element-citation></ref><ref id="R110"><label>110</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Rasmussen</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kelley</surname><given-names>CF</given-names></name><name name-style="western"><surname>Horton</surname><given-names>JP</given-names></name><name name-style="western"><surname>Jamieson</surname><given-names>DJ</given-names></name></person-group><article-title>Coronavirus disease 2019 (COVID-19) vaccines and pregnancy:What obstetricians need to know</article-title><source>Obstet Gynecol</source><year>2021</year><volume>137</volume><fpage>408</fpage><lpage>14</lpage><pub-id pub-id-type="pmid">33370015</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/AOG.0000000000004290</pub-id><pub-id pub-id-type="pmcid">PMC7884084</pub-id></element-citation></ref><ref id="R111"><label>111</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kao</surname><given-names>CM</given-names></name><name name-style="western"><surname>Orenstein</surname><given-names>WA</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name></person-group><article-title>The importance of advancing severe acute respiratory syndrome coronavirus 2 vaccines in children</article-title><source>Clin Infect Dis</source><year>2021</year><volume>72</volume><fpage>515</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">33527122</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1093/cid/ciaa712</pub-id><pub-id pub-id-type="pmcid">PMC7314192</pub-id></element-citation></ref><ref id="R112"><label>112</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Callaway</surname><given-names>E</given-names></name></person-group><article-title>Heavily mutated Omicron variant puts scientists on alert</article-title><source>Nature</source><year>2021</year><volume>600</volume><fpage>21</fpage><pub-id pub-id-type="pmid">34824381</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/d41586-021-03552-w</pub-id></element-citation></ref><ref id="R113"><label>113</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Barda</surname><given-names>N</given-names></name><name name-style="western"><surname>Dagan</surname><given-names>N</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>C</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name><name name-style="western"><surname>Lipsitch</surname><given-names>M</given-names></name><name name-style="western"><surname>Kohane</surname><given-names>IS</given-names></name><etal/></person-group><article-title>Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel:An observational study</article-title><source>Lancet</source><year>2021</year><volume>398</volume><fpage>2093</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">34756184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(21)02249-2</pub-id><pub-id pub-id-type="pmcid">PMC8555967</pub-id></element-citation></ref><ref id="R114"><label>114</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Kamar</surname><given-names>N</given-names></name><name name-style="western"><surname>Abravanel</surname><given-names>F</given-names></name><name name-style="western"><surname>Marion</surname><given-names>O</given-names></name><name name-style="western"><surname>Couat</surname><given-names>C</given-names></name><name name-style="western"><surname>Izopet</surname><given-names>J</given-names></name><name name-style="western"><surname>Del Bello</surname><given-names>A</given-names></name></person-group><article-title>Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>661</fpage><lpage>2</lpage><pub-id pub-id-type="pmid">34161700</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2108861</pub-id><pub-id pub-id-type="pmcid">PMC8262620</pub-id></element-citation></ref><ref id="R115"><label>115</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name name-style="western"><surname>Hall</surname><given-names>VG</given-names></name><name name-style="western"><surname>Ferreira</surname><given-names>VH</given-names></name><name name-style="western"><surname>Ku</surname><given-names>T</given-names></name><name name-style="western"><surname>Ierullo</surname><given-names>M</given-names></name><name name-style="western"><surname>Majchrzak-Kita</surname><given-names>B</given-names></name><name name-style="western"><surname>Chaparro</surname><given-names>C</given-names></name><etal/></person-group><article-title>Randomized trial of a third dose of mRNA-1273 vaccine in transplant recipients</article-title><source>N Engl J Med</source><year>2021</year><volume>385</volume><fpage>1244</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">34379917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2111462</pub-id><pub-id pub-id-type="pmcid">PMC8385563</pub-id></element-citation></ref><ref id="R116"><label>116</label><element-citation publication-type="webpage" publication-format="web"><source>US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes additional vaccine dose for certain immunocompromised individuals</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised">https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref><ref id="R117"><label>117</label><element-citation publication-type="webpage" publication-format="web"><source>European Medicines Agency. Cominarty and Spikevax: EMA recommendations on extra doses and booster</source><comment>Available from: <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.ema.europa.eu/en/news/comirnaty-spikevax-ema-recommendations-extra-doses-boosters">https://www.ema.europa.eu/en/news/comirnaty -spikevax-ema-recommendations-extra-doses-boosters</uri></comment><date-in-citation>accessed on December 20, 2021</date-in-citation></element-citation></ref></ref-list></back></article></pmc-articleset>